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 v 
Summary 
 
The RecQ family of DNA helicases is conserved from bacteria to human and 
members play an important role in the maintenance of genome stability. Humans 
possess five RecQ homologues: RECQL1, BLM, WRN, RECQL4, and RECQL5. 
Five autosomal recessive disorders, characterized by genomic instability, cancer 
progression, and developmental abnormalities, are associated with defects in the 
BLM (Bloom syndrome), WRN (Werner syndrome), and RECQL4 (Rothmund-
Thomson (RTS), RAPADILINO, and Baller-Gerold syndromes (BGS) genes 
products. While the distinct molecular functions of BLM and WRN helicases have 
been widely characterized in the last decade, the precise molecular and cellular 
role of the RECQL4 protein has not yet been elucidated. 
 The aim of this thesis was to investigate if RECQL4 is subject to reversible 
acetylation and how this post-translational modification influences RECQL4 
function in vivo. To this end, we overexpressed RECQL4 with different human 
histone acetyltransferases (HATs) in human embryonic kidney (HEK) 293T cells 
and examined RECQL4 acetylation in vivo using whole cell extracts and an α-
acetyl-lysine antibody. This experiment revealed that only p300, a human 
transcriptional co-activator and histone acetyltransferase, specifically acetylated 
RECQL4 in vivo. A RECQL4/p300 interaction was confirmed by co-
immunoprecipitation and ELISA-based protein binding assays and the interaction 
regions were mapped using GST-pull down experiments. The N-terminal amino 
acids 1-408 of RECQL4 and residues 1459–1892 of p300 were necessary and 
sufficient for the interaction of RECQL4 with p300. 
 We investigated the biochemical consequences of RECQL4/p300 
interaction. Therefore, RECQL4 and p300 were recombinantly expressed, 
purified and subsequently used to test RECQL4 ATPase activity. We showed that 
p300 specifically stimulated the RECQL4 ATPase activity in vitro, while 
acetylation of RECQL4 decreased this effect. 
 vi 
 We used an in vitro acetylation assay with purified recombinant p300, 
different GST-RECQL4 fragments, and 14C-labeled Acetyl-Coenzyme A (Ac-CoA) 
to identifiy several lysine residues (K 376, 380, 382, 385, 386) of the previously 
characterized RECQL4 nucleolar localization signal (NOS) (aa 376-386) as 
targets of p300 mediated acetylation. This finding was confirmed since RECQL4 
(K 376, 380, 382, 385, 386 R) mutant was no longer acetylated by p300 in vivo. 
 We next analyzed RECQL4 localization in human cells using 
immunofluorescence. As previously shown, overexpressed His-RECQL4 was 
predominantly localized to the nucleus in different human cell lines. Interestingly, 
mutation of the NOS lysine residues to alanine (K 376, 380, 382, 385, 386 A), but 
not to arginine (K 376, 380, 382, 385, 386 R), completely abolished the nuclear 
import of RECQL4 in human cells. Additionally, the fusion of the RECQL4 NOS 
(aa 376-386) to the N-terminus of β-galactosidase led to the nuclear import of 
this 100kDa protein in mammalian cells, indicating the importance of positively 
charged amino acid residues for the nuclear import of the RECQL4 protein. 
 Finally, we investigated the consequence of p300 mediated RECQL4 
acetylation on its subcellular localization. Immunofluorescence experiments 
showed that overexpression of p300, but not its catalytic dead mutant, enhanced 
about three-fold the number of cells in which RECQL4 was mainly cytoplasmic. 
No difference was seen when the corresponding RECQL4 mutant (K 376, 380, 
382, 385, 386 R) was used. The same effect was observed when cells were 
treated with the histone deacetylase (HDAC) inhibitors Trichostatin A (TSA) and 
nicotin amide (NA) indicating that protein acetylation drives RECQL4 from the 
nucleus to the cytoplasm. 
 Our results provide the first evidence of a post-translational modification of 
the RECQL4 protein and suggest that acetylation of RECQL4 by p300 regulates 
the trafficking of RECQL4 between the nucleus and the cytoplasm. 
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Zusammenfassung 
 
RecQ Helikasen spielen eine entscheidende Rolle in der Aufrechterhaltung 
genomischer Stabilitaet. Die Mitglieder der Familie der RecQ Helikasen sind 
hochkonserviert und es wurden im Menschen fuenf homologe Gene identifiziert: 
RECQL1, BLM, WRN, RECQL4 und RECQL5. Es ist bekannt, dass Mutationen 
in den BLM, WRN und RECQL4 Genen zu verschiedenen autosomal rezessiven 
Krankheiten führen: Mutationen im BLM Gen fuehren zum Bloom Syndrom, WRN 
Mutationen sind verantwortlich fuer das Werner Syndrom und RECQL4 
Mutationen werden mit drei verschiedenen Krankheiten assoziiert: Dem 
Rothmund-Thomson-, RAPADILINO- und Baller-Gerold Syndrom. Patienten mit 
diesen Krankheiten haben Anomalien waehrend der Entwicklung und ein 
erhoehtes Krebsrisiko, hervorgerufen durch genomische Instabilitaet in den 
Zellen. Waehrend die BLM- und WRN Helikasen gut erforscht sind und ihre 
zellulaeren Aufgaben zu einem grossen Teil charakterisiert wurden, ist die Rolle 
von RECQL4 weitgehend unbekannt.  
Das Ziel dieser Dissertation war es, herauszufinden, ob RECQL4 
reversibel aceyliert wird. Verschiedene Histon Acetyltransferasen (HATs) wurden 
zusammen mit RECQL4 in menschlichen Zellen (HEK 293T) ueberexprimiert und 
die Zellextrakte mittels einem α- Acetyl-Lysin Antikoerpers auf acetyliertes 
RECQL4 hin untersucht. Diese Experimente zeigen, dass RECQL4 spezifisch 
von der HAT p300 in vivo acetyliert wird. Die Interaktion zwischen RECQL4 und 
p300 konnten wir durch Co-immunopräzipitations- und ELISA Experimente 
bestaetigen. Des Weiteren bestimmten wir die interagierenden Regionen von 
RECQL4 und p300. Mit GST-pull down Experimenten haben wir nachgewiesen, 
dass das RECQL4 Fragment von Aminosaure 1 bis 408 und das p300 Fragment 
von Aminosaeure 1459 bis 1893 fuer die Interaktion der beiden Proteine 
ausreichen.  
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Zur Untersuchung der Funktion dieser Interaktion testeten wir den Einfluss 
von p300 auf die ATPase Aktivitaet von RECQL4. Wir verwendeten dazu 
rekombinant exprimierte und aufgereinigte RECQL4 und p300 Proteine. Wir 
konnten nachweisen, dass p300 die ATPase Aktivitaet von RECQL4 stimuliert, 
waehrend die Acetylierung von RECQL4 durch p300 eine leicht hemmende 
Wirkung hat.  
Als Naechstes untersuchten wir, welche RECQL4 Lysine von p300 
acetyliert werden. Mittels in vitro Acetylierungsassays mit aufgereinigtem p300, 
verschiedenen GST-RECQL4 Fragmenten und 14C-Acetly-Coenzym A 
identifizierten wir mehrere Lysine (K 376, 380, 382, 385, 386) innerhalb des 
RECQL4 Nukleolar Lokalisation Signal (NOS) als moegliche Ziele der 
Acetylierung. Die Tatsache, dass die RECQL4 (K 376, 380, 382, 385, 386 R) 
Mutante von p300 nicht laenger in vivo acetyliert wurde, bestaetigte dies. 
Des Weiteren untersuchten wir die Lokalisation von RECQL4 in humanen 
Zellen mittels Immunofluoreszenz. Wie bereits von anderen Gruppen gezeigt, ist 
endogenes sowie ueberexprimiertes RECQL4 Protein vor allem im Nukleus 
lokalisiert. Wir untersuchten zwei RECQL4 NOS Lysin Mutanten, (K 376, 380, 
382, 385, 386 A) und (K 376, 380, 382, 385, 386 R), auf ihre Lokalisation. 
Interessanterweise war die (K 376, 380, 382, 385, 386 A) Mutante 
ausschliesslich im Zytoplasma lokalisiert, waehrend sich die (K 376, 380, 382, 
385, 386 R) Mutante wie der RECQL4 Wildtyp verhielt. Die N-terminale Fusion 
des RECQL4 NOS (aa376-386) an β-Galaktosidase fuehrt zum Import in den 
Nukleus dieses 100kDa Proteins, was die Relevanz der RECQL4 
Aminosaeuresequenz 376-386 fuer den nuklearen Import weiter unterstreicht.  
Zu guter Letzt wollten wir den Einfluss p300-vermittelter Acetylierung auf 
die Lokalisation von RECQL4 studieren. Immunfluoreszenz Experimente zeigen, 
dass die Ueberexprimierung von p300 die RecQL4 Lokalisation im Zytoplasma 
signifikat erhoehte, waehrend die ueberexprimierte katalytisch-inaktive p300 
Mutante keinen Einfluss hatte. Derselbe Effekt wurde erzielt, wenn die Zellen mit 
Histon Deacetylase Inihbitoren Trichostatin A und Nikotinamid behandelt wurden. 
 ix 
Wir schliessen daraus, dass die Acetylierung von RECQL4 fuer die 
zytoplasmatische Lokalisation von RECQL4 verantwortlich ist.  
Die hier gezeigte Acetylierung von RECQL4 durch p300 ist der erste Nachweis 
einer posttranslationeller Modifikation von RECQL4. Des Weiteren zeigen wir, 
dass sie eine wichtige Rolle in der Lokalisation von RECQL4 spielt. 
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1 Helicases 
 
Helicases are motor proteins that can transiently catalyze the unwinding of 
energetically stable duplex nucleic acids (DNA-DNA, RNA-DNA, RNA-RNA) using 
NTP hydrolysis as the energy source. They are important enzymatic tools for the 
cellular DNA machinery and play essential roles in nearly all aspects of nucleic acid 
metabolism, such as DNA replication, repair, recombination, and transcription (1, 2). 
 In 1976, the first helicase was discovered in Escherichia coli (E. coli) (3) and 
since then, a large number of these enzymes have been identified and characterized 
in many different organisms. Helicases can be classified according to sequence 
homology and directionality. Most helicases require a single-stranded nucleic acid 
region to bind and initiate the action of strand separation. Once loaded on the strand, 
they show a directional bias and translocate either 5’→3’ or 3’→5’ (Fig. 1). The 
directionality is defined with respect to the nucleic acid strand on which the enzyme 
translocates.  
 
 
 
 
 
 
 
 
 
Based on conserved amino acid sequence motifs, helicases are classified into 
families and superfamilies (SF1-4) (4). Helicases from different families share 
similarities in their three-dimensional folds (RecA-like folds) (5-7). SF1 and SF2 
represent the largest and most closely related groups of helicases, and contain at  
 
 
Figure 1: Polarity of protein translocation along a DNA strand 
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least seven conserved motifs (I, Ia, II-VI), SF3 helicases have three motifs (A, B and 
C), and SF4 members have five motifs (1, 1a, 2-4) (8). All helicases, irrespective of 
the superfamily to which they belong, contain motifs that are equivalent to the so-
called Walker A and B motifs, characteristic of NTP-binding and/or hydrolyzing 
enzymes, which were first identified in mitochondrial F1-ATPase (9). 
 Figure 2 shows the organization of the conserved DEAD box helicase 
domains. Motif I is necessary for ATP binding (10) and referred to as the Walker A 
motif found in ATPases (9). The motif Ia is present in most SF1 and SF2 helicases 
(11) and binds ssDNA in the UL9 helicase from the Herpes Simplex Virus (HSV) (11). 
DEAD and DExH helicases exhibit an additional motif named Ib, which has the 
consensus sequence of TxGx  (2). Motif II, also named the Walker B motif, is also 
found in other ATPases. Based on the sequence of this motif, helicases are further 
classified into the DExH and the DEAD families. The highly conserved aspartate 
residue (D of DE) in this motif coordinates Mg2+, and is required for ATP hydrolysis 
(10). Motif III reveals a role in coupling ATP hydrolysis to strand separation (12). Motif 
IV seems to be essential for the later steps of the ATPase reaction as it binds ADP. 
Motif V makes contacts with the sugar-phosphate backbone and is therefore likely to 
serve as an additional DNA binding domain (8). Motif VI has been proposed to be 
required for the helicase to move along the DNA by mediating conformational 
changes associated with nucleotide binding (2). 
 
 
 
 
 
 
 
Figure 2: Schematic representation of conserved helicase motifs of the DEAD box helicases. 
The colored boxes represent the conserved helicase motifs, and the consensus amino acid sequence 
of each motif is shown by the single letter code inside the boxes (Adapted from (2)). 
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Much effort has been made in the past to understand how DNA helicases are 
able to simultaneously interact with NTP and nucleic acids, hydrolyze NTP, and 
couple the energy resulting from nucleotide hydrolysis to DNA unwinding. Different 
models have been proposed to describe the helicase catalyzed mechanism of 
unwinding  (13-17) (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Different proposed models for the active unwinding mechanisms for DNA helicases.  
For all of the mechanisms depicted, DNA unwinding is fuelled by the energy of helicase-catalysed NTP 
hydrolysis (18). 
 
 
In the inchworm model (19) (Fig. 3A), the functional helicase has two non-
identical DNA-binding sites that bind with a defined polarity; the leading site interacts 
with the duplex region during successive cycles of unwinding, whereas the tail site 
interacts with the ssDNA. A co-operative inchworm mechanism has been proposed in 
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which multiple helicase molecules line up along the ssDNA lattice (20, 21) (Fig. 3B). 
The rolling model requires at least two identical DNA-binding sites, both of which can 
bind to ssDNA and dsDNA, in an alternating fashion (Fig. 3C). The rolling model 
requires a dimeric protein, whereas the inchworm model is consistent with any 
oligomeric state, including a monomer. An alternative multimeric form is the 
hexameric helicase, which is believed to have a ring structure that encircles one 
strand of the duplex leaving the other extruded outside the ring (Fig. 3D). The 
hexameric helicase may have an advantageous design to prevent.  
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2 RecQ Family of DNA Helicases 
 
RecQ DNA helicases are wide spread in nature and have been identified in 
organisms ranging from bacteria to humans. All RecQ homologues tested to date 
unwind paired DNA, translocating in a 3′→5′ direction (22). A single family member 
exists in bacteria and budding or fission yeast, whereas there are generally multiple 
representatives in higher eukaryotes, including five identified RecQ proteins in 
humans: RECQL1, BLM, WRN, RECQL4, RECQL5 (Fig. 4).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Representation of selected members of the RecQ family of DNA helicases.  
The name of this family derived from the bacterial (E. coli) DNA helicase RecQ. Proteins are aligned 
by their conserved helicase domains (green boxes). Poorly conserved regions of each protein are 
shaded in light grey. Three splice variants of the human RECQL5 protein are expressed, only one of 
which is shown. The size of each protein in amino acids is indicated on the right. (Adapted from (23)). 
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All members share a central helicase domain, comprised of approximately 450 amino 
acids, which contains the seven conserved motifs including the Walker A and B 
boxes involved in ATP binding, and a DEXH box that defines this helicase family 
(24). In most RecQ helicases, the region that is carboxy-terminal to this domain 
contains two motifs: the RecQ C-terminal (RQC) domain, which is also a 
characteristic of the RecQ family and appears to mediate protein-protein interactions 
and the HRDC domain that might be involved in DNA binding (24). Some of the RecQ 
family members contain a highly acidic region at the N-terminus, which may mediate 
protein interactions DNA interactions, or both. Finally, human WRN helicase contains 
an exonuclease domain. Outside of these domains, there is little sequence similarity 
between family members.  
 The first RecQ helicase was identified over 20 years ago in E. coli through a 
screen for mutants resistant to thymineless-death (25). Recently, the 1.8 Å resolution 
structure of the catalytic core of E. coli RecQ was determined (26). The RecQ core 
comprises four conserved subdomains, two of these combine to form its helicase 
region, while the others form Zn2+ -binding and winged-helix motifs (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Structures of conserved RecQ domains  
(A) Crystal structure of the E. coli RecQ catalytic core. Helicase lobes are coloured pink and blue, the 
Zn2+-binding domain and winged helix domain of the RQC region are in yellow and green 
respectively. (B) Close-up of the ATP binding site in the structure of the ATP[S]-bound E. coli RecQ 
catalytic core. A bound Mn2+ ion is shown as a cyan sphere. (C) Crystal structure of the E. coli RecQ 
HRDC domain (18). 
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The winged-helix motif shares significant structural similarity with other DNA binding 
proteins, thus identifying a likely DNA binding site in E. coli RecQ. It was shown that 
E. coli RecQ is a component of the RecF pathway of recombinational repair (25). 
Additionally, RecQ helicase activity has also been shown to function in suppressing 
illegitimate recombination, rescuing stalled replication forks and promoting induction 
of the SOS response in E.coli (27-29). Thus, E.coli RecQ is important for cellular 
genome maintenance and its activities are linked by its helicase function. Members of 
the RecQ family of DNA helicases are involved in processes linked to DNA 
replication, DNA recombination, and gene silencing (30).  
 Out of the five human RecQ homologues, three have been shown to be 
associated with five autosomal recessive disorders characterized by genomic 
instability and cancer predisposition. Werner syndrome (WS) has been linked with 
mutations in the WRN gene (31) and mutations in the BLM gene have been found to 
cause Bloom syndrome (BS) (32). Interestingly, three different human disorders have 
been associated with mutations in the RECQL4 gene: Rothmund-Thomson (RTS), 
RAPADILINO and Baller-Gerold (BGS) syndromes (33-35). In the last decade a huge 
effort was made to understand the underlying molecular mechanisms of these 
disorders.  
 Below, is a summary of the recent findings and highlighting the importance of 
studying human RecQ family members in order to understand their role in the 
maintenance of genome stability. 
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2.1 RECQL1 
 
 
2.1.1 General Information 
 
RECQL1 is the smallest human RecQ family member, being only slightly larger in 
size than E.coli RecQ (36). The RECQL1 gene is located on chromosome 12p11-12 
and encodes a 649 amino acid protein. It was originally cloned by two independent 
groups (37, 38). So far, no genetic disease has been linked to mutations in the 
RECQL1 gene and the cellular function of the RECQL1 protein remains mainly 
elusive. 
 
 
2.1.2 Biochemical Properties of RECQL1 Protein 
 
Purified RECQL1 exhibits low processivity helicase activity and was originally found 
as a dimer in solution (39). RECQL1 alone is capable of unwinding short DNA 
duplexes (<110 bp) but requires human replication protein A (hRPA) in order to 
unwind longer substrates (501 bp) (40).  Additional biochemical studies revealed that 
RECQL1 is able to unwind homlogous recombination (HR) intermediates such as 
Holliday junctions (HJ) and D-loop structures (41). Furthermore, RECQL1 catalyzes 
efficient strand annealing between complementary ssDNA molecules and this activity 
is inhibited by ATP binding (41). Very recent size exclusion chromatography and 
transmission electron microscopy data indicate that RECQL1 is found in two 
quaternary forms: higher-order oligomers consistent with pentamers or hexamers, 
and smaller oligomers consistent with monomers or dimers.  RECQL1 seems to 
anneal ssDNA as a pentamer or hexamer, while it unwinds DNA as a monomer or 
dimer (42). 
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2.1.3 RECQL1 Interacting Partners 
 
In 1997, Qip1 and Rch1, two human importin α homologues involved in nuclear-
cytoplasmic transport, were identified as RECQL1 interacting partners in a yeast two-
hybrid (YTH) screen (43) (Fig. 6).  This interaction was confirmed by the finding that 
Qip1 is able to mediate nuclear transport of bovine serum albumin (BSA) when 
conjugated to the RECQL1 nuclear localisation signal (NLS) (44). RECQL1 is also 
reported to physically interact with topoisomerase IIIα (Top3α) (45), but the functional 
importance of RECQL1 interactions with Top3α has not been demonstrated. In 2005, 
Doherty et al. showed that RECQL1 is associated with several mismatch repair 
proteins.  RECQL1 stimulates the incision activity of human exonuclease 1 and the 
mismatch repair recognition complex MSH2/6 stimulated RECQL1 helicase activity in 
vitro, suggesting a role of RECQL1 in the context of mismatch repair. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: RECQL1-interacting partners and their function 
The few interacting partners of RECQL1 identified so far suggest different roles in replication and 
mismatch repair. 
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2.2 BLM 
 
 
2.2.1 Bloom Syndrome  
 
Bloom syndrome (BS) was originally described 1954 by the dermatologist David 
Bloom (46). It is an extremely rare, autosomal recessive genetic disorder 
characterized by proportional dwarfism, skin erythema (skin lesion), immune 
deficiency, type II diabetes mellitus and very high incidence of cancers of most types, 
with a very early average age of onset. Male patients are sterile, while female 
patients are subfertile (47).  
 
 
 
 
 
 
 
 
 
 
 
Source: Yale Pediatrics Resident's Website (48). 
 
 
 
 
BS is caused by various mutations in the BLM gene, located on chromosome 
15q26.1 (49). These mutations are predominantly nonsense or frameshift mutations, 
leading to a premature termination codon and expression of truncated BLM protein. 
 
Figure 7: Bloom syndrome patients 
Both patients suffer from telangiectatic erythema caused by UV hypersensitivity.  
Source: Geneva Foundation for 
 Medical Education and Research  
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Truncated BLM protein is found in the cytoplasm due to the lack of its C-terminal 
NLS. Approximately 15% of BS cases are due to missense mutations in BLM, and 
these mostly map to exons encoding the helicase domain resulting in catalytic 
inactive BLM protein. 
Cell lines established from BS patients show elevated levels of gaps, breaks 
and structurally rearranged chromosomes (50, 51). However, the hallmark feature of 
BS cells, which is used in diagnosis in humans, is the approximately 10-fold increase 
in the frequency of sister-chromatid exchanges (SCEs) (52). The SCEs are generally 
thought to represent HR events occurring between sister chromosomes during S 
phase or G2. 
 
 
2.2.2 BLM Mouse Models 
 
In 1998, Chester et al. created the first BLM knockout mouse model (53). Gene 
disruption resulted in integration of the phosphoglycerate kinase (PGK)–neo cassette 
upstream of the BLM helicase homology region. Blm−/− mice were developmentally 
delayed and died by embryonic day 13.5. Fibroblasts derived frome these embryos 
showed elevated levels of SCE.  
Two years later Luo et al. generated viable Bloom mice that were prone to a 
wide variety of cancers (54). They used embryonic stem (ES) cell technology to 
replace exon 2 with a loxP-PGK-neo cassette. This Bloom mouse model was a good 
tool for studying the underlying mechanism leading to genomic instability and cancer 
predisposition in Bloom syndrome. Their study showed that, in the absence of BLM 
function, mouse ES cells had an increased frequency of gene targeting, indicative of 
an increased frequency of homologous recombination. This is consistent with the 
high SCE rate observed from cells derived from these BLM deficient mice.  
The third BLM mouse model was generated by Goss et al. in 2002 (55). In 
contrast to the mouse models mentioned above, they used a gene targeting construct 
in which exons 10, 11, and 12 of Blm were replaced with a hypoxanthine 
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phosphoribosyltransferase (Hprt) cassette, mimicking a mutation that is widespread 
among BS patients. These mice developed lymphoma earlier than wild-type 
littermates in response to challenge with murine leukemia virus and developed twice 
the number of intestinal tumors when crossed with mice carrying a mutation in the 
Apc tumor suppressor. These observations indicate that Blm is a modifier of tumor 
formation, a finding with important implications for cancer risk in humans. 
 
 
2.2.3 BLM Interacting Partners 
 
According to countless interaction studies of BLM and associated proteins, numerous 
models for BLM function have been proposed and BLM may be involved in DNA 
repair, homologous recombination, DNA replication, apoptosis and telomere 
maintenance (47). A complete list of all BLM interacting partners is found in Figure 8. 
Below, the most relevant BLM interacting partners are discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: BLM-interacting partners and their function 
BLM binds to a variety of proteins, suggesting roles for BLM in many aspects of DNA transactions 
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The PML gene was originally identified as the site of translocations in cases of 
acute promyelocytic leukaemia (56). The PML protein functions as a tumor 
suppressor and was found to localize into specific structures called PML bodies, 
where many proteins involved in DNA metabolism are localized (57-59). BLM co-
localizes with PML in most cells, but co-localization is never complete (60). This 
suggests a regulated association of the two proteins, and that PML bodies might, 
therefore, be temporary storage sites for BLM. It seems that BLM shuttles to and 
from PML bodies while effecting its function. 
Wang et al. have identified a high-order complex consisting of many DNA 
repair factors, BLM amongst them, and called it BASC, standing for BRCA1-
associated genome surveillance complex (61). Many tumor suppressors and DNA 
damage repair proteins are found in this complex: ATM, BLM, BRCA1, MSH2, MSH6, 
MLH1, RAD50-MRE11-Nbs1 (MRN complex) and RFC. Members of the BASC 
complex have roles in recognition of abnormal DNA structures or damaged DNA, 
which implicates that BASC might play a role as a DNA damage sensor. Upon 
hydroxyl urea (HU) treatment, BLM, BRCA1 and PCNA co-localize, suggesting a 
common role in replication repair (61, 62). 
Upon Immunoprecipitation of BLM from HeLa cells, Meetei et al. identified by 
masspectrometric methods a complex that includes BLM, Top3α, RPA and the five 
core Fanconi anemia (FA) proteins FANCA, FANCC, FANCE, FANCF and FANCG 
and called this complex BRAFT. BLM is responsible for the unwinding activity in this 
complex (63). Pichierri et al. have shown that BLM and FANCD2 colocalise and co-
immunoprecipitate upon treatment with DNA crosslinkers or agents inducing 
replication fork arrest, again indicating a functional interaction (64). The features of 
the BS are very different to those of the FA, but some aspects of genomic instability 
in these diseases are similar. 
Rad51 protein is an ortholog of the bacterial RecA protein, which plays a 
central role in HR and DNA repair. Rad51 forms a nucleoprotein filament on ssDNA 
to mediate strand exchange, an important step in the initiation of HR. BLM and the 
human Rad51 have been shown to interact both in vivo and in vitro (65) and they co- 
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localize in certain untreated cells. Upon IR or aphidicolin treatment, the number of 
BLM and RAD51 co-localizing foci increases (66). This data suggest a role of BLM in 
the context of DNA DS repair by HR. 
BLM and p53 interact physically and functionally in vitro and in vivo (67-69). 
p53 inhibits the unwinding activity of BLM on HJs, but not on standard oligonucleotide 
substrates, indicating that p53 might be involved in the regulation of HR through 
modulating the interaction of BLM with recombination intermediates (69). Additionally, 
Wang et al. found that BLM and p53 might regulate apoptosis because ectopically 
expressed p53 induces apoptosis in normal cells but not in BS cells. Furthermore, BS 
cells show normal Fas-induced apoptosis, and therefore the effect seems to be 
specific for the p53 apoptotic pathway (68).  
The replication protein A (RPA) is a heterotrimeric ssDNA binding protein that 
is formed by subunits of 14, 32 and 70 kDa. BLM interacts physically with RPA 
through the p70 subunit (70, 71) and co-localizes with RPA (72). RPA stimulates 
helicase activity of BLM (70). 
  Top3α catalyses the interconversion of different topological isomers of DNA. 
BLM and Top3α co-localize to PML nuclear bodies in fibroblasts (73) but Top3α is 
not localized correctly in BS cells (45). In addition, BLM interacts functionally with 
Top3α and it stimulates the relaxation of negatively supercoiled plasmid DNA 
catalyzed by Top3α.  
 Human RMI1 cooperates with BLM and Top3α to catalyze double Holliday 
junction (DHJ) dissolution (74). Moreover, the role of RMI1 is mediated through a 
specific interaction with Top3α and RMI1 promotes the recruitment of Top3α to 
DHJs. The mechanistic significance of the BLM/ Top3α interaction is discussed in 
detail in the BLM Biochemistry section below. 
Different data suggest that BLM might also be involved in the maintenance of 
telomere stability.  TRF1 and TRF2 are homodimeric proteins that have been shown 
to bind exclusively to double-stranded telomeric DNA. BLM has been shown to 
interact with TRF2 in vitro and in vivo  and TRF2 stimulates BLM helicase activity 
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(75). Both of these proteins co-localize with BLM in atypical, telomere-associated 
PML bodies (76).  
Our group demonstrated the physical and functional interaction between BLM 
and the chromatin assembly factor 1 (CAF-1) (77). BLM and hp150, the largest 
subunit of CAF-1, are found in complex in vivo and they co-localize upon DNA 
damage treatment. Furthermore, BLM inhibits CAF-1 mediated chromatin assembly 
during DNA repair in vitro (77).  These findings point out the coordinate way of BLM 
and CAF-1 function to promote cell survival in response to DNA damage and 
replication blockade. 
 
 
2.2.4 Biochemical Properties of the BLM Protein 
 
In 1997, Karow et al. purified recombinant human BLM protein from S. cerevisiae. 
BLM was shown to possess ATP and Mg+2 dependent 3’→5’ helicase activity (78). 
Electron microscopy and size exclusion experiments indicated that BLM protein is a 
hexamer in its active form and the N-terminal domain is crucial for the oligomerization 
(79).  
Different studies indicate that BLM can unwind several DNA substrates such 
as synthetic HJs, G4 DNA and D-loop structures (80, 81). Additionally, BLM 
promotes the annealing of ssDNA, an activity that does not require Mg2+, is inhibited 
by ssDNA binding proteins and ATP, and is dependent on DNA length (82).  
The most important biochemical finding on BLM was discovered by Ian 
Hickson’s group. They describe that BLM, in conjunction with Topo IIIα, is able to 
resolve double holliday junctions (DHJ) via a strand passage mechanism that 
prevents exchange between flanking sequences (83). The underlying mechanism 
was called DHJ dissolution. DHJs are intermediates in meiotic recombination (84) 
and are predicted to form in mitotic cells during repair of DSBs by HR.  
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2.2.5 Posttranslational Modifications of BLM Protein 
 
BLM is posttranslationally modified by phosphorylation (85-89) and sumoylation (90). 
Originally, data indicate that BLM, in response to ionizing radiation, is phosphorylated 
and accumulates through an ATM-dependent pathway, suggesting that BLM acts as 
an ATM kinase downstream effector (85).  In addition, BLM is phophorylated by ATR 
following exposure of cells to HU (88). BS cells ectopically expressing a BLM mutant 
unable to be phosphorylated, fail to recover from HU-induced replication blockade.  
Recent findings identified BLM as a phosphorylation substrate for two other 
kinases: The mitotic Cdc2 kinase and the spindle assembly checkpoint kinase MPS-1 
(86, 89) suggesting additional roles for BLM in the context of mitosis and accurate 
chromosome segregation.  
In 2005, Eladad et al. showed that BLM is sumoylated on several lysine 
residues (90). BLM proteins that are mutated on their SUMO modification site fail to 
localize to PML nuclear bodies and they induce formation of DNA damage induced 
(DDI) foci in the absence of treatment with DNA damaging agents, suggesting that 
sumoylation of BLM regulates its intra-nuclear trafficking (90). 
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2.3 WRN 
 
 
2.3.1 Werner Syndrome  
 
Werner syndrome (WS) was first described by the medical student Otto Werner 
within his dissertation in 1904.  He reported three cases of young WS patients who 
showed ocular cataract accompanying hard scleroderma-like changes in the skin.  In 
1992, the causative gene locus was mapped (8p12) (91) and four years later, after 
extensive positional cloning, WRN was identified as the gene encoding a DNA 
helicase (31). 
 
 
 
 
 
 
 
 
Figure 9: Werner syndrome and accelerated aging (Adapted from (92)). 
 
 
 WS is a rare autosomal recessive disorder characterized by many clinical 
features, however, the hallmark of WS is accelerated aging (93-95). WS patients 
often suffer from bilateral ocular cataracts, type 2 diabetes mellitus, osteoporosis, 
various forms of arteriosclerosis, and hypogonadism at a relatively young age. The 
aged appearance is due to short stature, premature graying and loss of hair, 
scleroderma-like skin changes, and regional atrophy of subcutaneous fat. WS 
subjects have an elevated risk of various cancers, particularly sarcomas (96). The 
age of death varies between approximately 30 and 65 years, with a mean of 47 
years, and usually results from cancer or cardiovascular disease (94, 97, 98).  
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 All mutations in the WRN gene examined so far are either nonsense or 
frameshift mutations, leading to premature stop codons and expression of truncated 
WRN protein lacking the C-terminal NLS. These findings imply that both WS and BS 
are not only helicase diseases but in molecular terms they are also nuclear 
transportation disorders. 
 Fibroblasts derived from WS patients display limited replicative potential, 
prolongation of S-phase and hypersensitivity to 4-nitroquinoline-1-oxide (4-NQO) 
(99). Chromosomal analysis of WS cells revealed an overall genomic instability 
including frequent pseudodiploidy, with variable structural rearrangements associated 
with a high proportion of deletions. WRN primarily localizes to the nucleolus in all 
cells examined, and translocates to the nucleoplasm upon genotixic stress (100, 
101). 
 
 
2.3.2 WRN Mouse Models 
 
Three WRN mutant mice have been created by several groups thus far (102-104). 
The first model consists of a deletion of part of the helicase domain of the murine 
WRN homologue (102). These mice exhibited an enhanced sensitivity to 
camptothecin (the DNA topoisomerase 1 inhibitor), increased genomic instability, 
telomere attrition, and increased tumor occurrence (in particular in a poly (ADP-
ribosyl) polymerase-1 null or p53 null background). Cells derived from these mice 
showed premature loss of their proliferative capacity (102, 105). Although the tumor 
spectrum has been studied extensively in this model, the other phenotypes normally 
associated with human WS have not been analyzed.  
The second model consists of a mutation that eliminates the expression of the 
C-terminal region of WRN (103). The resulting mouse model is a WRN-null mutant as 
no WRN protein was detected using antibodies against either the N- or the C- 
terminal region of the protein.  
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The phenotypes reported for WS patients were not observed in these mice. However, 
crosses between WRN-null and TERC-null mice (knock out for the gene encoding the 
telomerase RNA component) recapitulated several symptoms associated with WS in 
humans in a subset of mice (106).  
Wang et al. generated a third model by introducing a human cDNA with a 
dominant-negative mutation in the helicase domain into mice (104). Although the in 
vivo phenotype was not reflecting the situation in humans, cells derived from these 
transgenic mice exhibited a slow growth phenotype in culture and a hypersensitivity 
to the DNA damaging agent 4-NQO. 
Taken together, no animal model of WS to date accurately mimics the human 
disorder. This might be due to differences between humans and mice in maintaining 
genomic stability. 
 
 
2.3.3 WRN Interacting Partners 
 
Although different genetic and biochemical studies have so far failed to establish a 
definite cellular role of WRN, characterizing the interaction with different protein 
partners might help to delineate the principal pathways in which WRN participates. 
WRN physically and functionally interacts with a variety of proteins (Fig. 10), 
suggesting a role for WRN in telomere maintenance, DNA replication, recombination, 
and repair. Below, the most prominent WRN interacting partners are discussed. 
One of the first physical and functional interactions was found in co-
immunoprecipitation studies identifying PCNA and topoisomerase I as two WRN-
interacting components. PCNA acts as a processivity factor for DNA polymerase 
delta in eukaryotic cells. Since DNA polymerase δ (pol δ) is also involved in 
resynthesis of excised damaged DNA strands during DNA repair, PCNA is important 
for both DNA synthesis and DNA repair (107). 
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Figure 10: WRN-interacting partners and their function 
WRN binds to a variety of proteins, suggesting roles for WRN in many aspects of DNA metabolism 
(112). 
 
The WRN exonuclease domain contains a region that is homologous to the PCNA 
binding motif (108, 109) found in many proteins involved in DNA replication and 
repair, such as FEN-1 and DNA ligase 1 (110, 111).  WRN co-localizes with PCNA at 
replication foci of primary cells, suggesting a possible role in DNA replication. 
Topoisomerases change the linking number of DNA during DNA replication in 
order to relive torsional stress caused by the advancing replication fork. Recent 
studies reveal that WRN physically interacts with topoisomerase I. WRN stimulates 
topoisomerase I to relax negatively supercoiled DNA while topoisomerase I inhibits 
WRN ATPase activity (113). Furthermore, WS cells are hypersensitive camptothecin 
during G2 and S phases of the cell cycle (114, 115). 
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 WRN has also shown to be associated with the major replicative DNA pol δ 
(116). WRN stimulates yeast pol δ primer extension in vitro, but has no effect on 
PCNA-pol δ complex processivity, indicating that WRN is not directly involved in 
normal processive DNA synthesis mediated by pol δ. It was shown that WRN instead 
helps pol δ by unwinding physical barriers like quadruplex DNA that block pol δ-
catalyzed DNA synthesis (117). 
 Another important protein that associates with WRN is human RPA, a 
heterotrimeric, single-stranded DNA binding protein required for DNA replication, 
recombination, and repair (118). Co-immunoprecipitation- and ELISA-based protein 
binding assays revealed a direct physical interaction between the two proteins. RPA 
markedly stimulates the DNA helicase activity of the WRN protein (119, 120) and 
increases its ability to unwind forked telomeric DNA structures (121, 122). While 
WRN alone cannot unwind partial duplexes longer than 40 bp, its interaction with 
RPA allows it to unwind substrates as long as 849 bp, the longest substrate tested 
(119). 
 FEN-1 is an interesting replication protein that directly interacts with WRN 
(123). FEN-1 possesses 5’-endonuclease/5’–3’-exonuclease activity and is involved 
in Okazaki fragment maturation during lagging strand DNA replication (124), long-
patch base excision repair (BER) (125), as well as non-homologous DNA end joining 
(NHEJ) (126). WRN greatly stimulates (more than 80-fold) the nucleolytic activity of 
FEN-1 in a concentration-dependent manner, even if the helicase and exonuclease 
activities of WRN are abolished (123). Additionally, WRN stimulates the cleavage of 
DNA structures that are poor substrates of FEN-1 alone, indicating that these two 
proteins are likely to act together in vivo. 
 The DNA-dependent protein kinase (DNA-PK), consisting of Ku70/Ku80 
heterodimer and DNA-PKcs, is an important player in processes like NHEJ and VDJ 
recombination (127, 128). WRN was found to interact physically with the Ku complex 
and DNA-PKcs in vitro and in vivo (129-134). The Ku complex stimulates the WRN 
exonuclease activity but does not affect its helicase activity (129). 
WRN protein seems to be involved in the process of DNA DSB repair. 
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WRN binds to DNA polymerse β (pol β) and stimulates strand-displacement 
DNA synthesis of  pol β in vitro in a reaction requiring the helicase domain of WRN 
(135). pol β  is a key polymerase in BER (136). Additionally, GST-pulldown- , ELISA-, 
as well as dot blot assays and immunofluorescence experiments show that WRN 
forms a complex with the human apurinic/apyrimidinic endonuclease-1 (APE-1), a 
key player in the early stages of BER. However, the exact molecular role of WRN in 
BER remains elusive. 
p53, the key tumor suppressor, directly associates with the C-terminal portion 
of WRN, and inhibits its exonuclease activity (137, 138). Wild type p53 diminishes 
WRN helicase activity and abolishes its ability to unwind synthetic HJ in vitro. This 
inhibition is dependent upon the phosphorylation of p53 (69). On a cellular level, p53 
is a repressor of the WRN gene transcription (139). 
The physical association of telomeric repeat binding factor 2 (TRF-2) and 
WRN protein (140) in conjunction with biochemical data demonstrating the disruption 
of D loops (structures formed at telomeres) by WRN protein (141, 142), suggests that 
WRN may participate in the maintenance of telomeres. Furthermore, WRN protein 
has been shown to be involved in the synthesis of the lagging strand of telomeres 
(143).  
Another protein complex that has been shown to cooperate with WRN is the 
MRN complex (144), a three-subunit complex that is composed of Mre11, Rad50, 
and Nbs1/Xrs2 (145). Mutations in these genes lead to sensitivity to DNA damage, 
genomic instability, telomere attrition, and aberrant meiosis (145). WRN co-localizes 
and physically interacts with the MRN complex at stalled replication forks (62) and 
the interaction is mediated by Nbs1. Furthermore, MRE11 promotes WRN helicase 
activity (146). Since depletion of Mre11 by RNAi knockdown does not enhance 
chromosomal breakage and cell death in WS cells, it is proposed that WRN and 
Mre11 act in a common pathway in response to replication fork arrest (147). 
Jiao et al. show that WRN interacts physically with the largest subunit of CAF-
1, hp150, in vitro and in vivo (148). In the absence of WRN, hp150 does not re-
localize to form nuclear foci following treatment of cells with hydroxyurea (HU), 
whereas in hp150 RNAi knockdown cells, WRN localization was unaffected. These 
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results indicate that before CAF-1, WRN responds to DNA damage and WRN may 
recruit CAF-1, via hp150, to DNA damage sites to assemble the newly synthesized 
DNA into chromatin following DNA synthesis. 
 
 
2.3.4 Biochemical Properties of WRN Protein 
 
The human WRN protein is a 1432 amino acid protein with a predicted molecular 
mass of 170 kDa. Size exclusion chromatography data suggest oligomerization of 
WRN in vivo, most likely as a trimer (149). WRN protein is unique among the five 
human RecQ members in that it is a bipartite and bifunctional Enzyme: In addition to 
ATP-dependent 3′-5′ helicase and ssDNA-dependent ATPase activities, it also 
possesses a functional 3′-5′ exonuclease domain, which is similar to the exonuclease 
domain of E. coli DNA polymerase I. The WRN enzymatic activities are separable 
from each other (150). As a helicase, WRN shows poor processivity and 
preferentially unwinds bubble substrates, forked structures and G-quadruplex DNA 
(80). As shown for BLM, WRN is also capable of branch migrating HJs over 
distances of several kb (151). WRN exonuclease activity displays low processivity on 
substrates such as ds duplexes with blunt ends. The preferred WRN exonuclease 
substrate is a partial duplex with a single 3’ mismatch, suggesting a role analogous to 
the proofreading exonuclease activity of replicative DNA polymerases (150).  
 
2.3.5 Posttranslational Modifications of WRN Protein 
 
WRN was found to be phosphorylated in vivo after bleomycin treatment or in 
replication stress (146, 152, 153). Several studies revealed that four kinases seem to 
be involved in WRN serine/threonine and tyrosine phosphorylation in vivo:  
ATM/ATR, DNA-PKcs, and c-Abl. On the basis of the consensus of ATM 
phosphorylation sites, WRN has been predicted to be a substrate of this kinase (154) 
and Pichierri et al. suggested an ATR dependent phosphorylation of WRN following 
replication arrest and DNA damage induced during the S phase of the cell cycle 
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(153).  DNA-PKcs phosphorylates WRN together with Ku70/Ku80 as a heterotrimeric 
complex in vitro and in vivo (133, 152, 155), leading to inhibition of WRN helicase 
and exonuclease activity.  WRN was found to be constitutively associated with c-Abl 
and upon bleomycin treatment WRN is phosphorylated on a tyrosine residue and 
dissociates from c-Abl. Furthermore, c-Abl phosphorylation also inhibits WRN 
exonuclease and helicase activity (146). It will be of particular interest to unravel the 
role of ATM in WRN phosphorylation and its impact on the role of WRN in DNA 
damage response. 
 Using a yeast two-hybrid approach, Ubc9 was found as a prominent WRN 
interacting partner. Ubc9 belongs to the family of ubiquitin ligases and is required for 
WRN sumoylation in vivo (156). It has been proposed that SUMO modification may 
play a role in the WRN nuclear re-localization (157). Nevertheless, the functional 
consequence of WRN sumoylation needs to be further characterized.  
 In addition to phosphorylation and sumoylation, acetylation of WRN has been 
reported (158). WRN is acetylated by the histone acetyltransferse p300 in vivo, and 
this results in translocation of WRN protein from the nucleolus to nuclear foci (158). 
  
 25 
2.4 RECQL4 (adapted from Dietschy et al.) 
 
 
2.4.1 Rothmund-Thomson Syndrome  
 
 RTS was originally described in 1868 by the German ophthalmologist 
Rothmund (159) and subsequently confirmed by the English dermatologist Thomson 
in 1936 (160). It is an unusual autosomal recessive defect composed of diverse 
symptoms like poikiloderma, growth deficiency, juvenile cataracts, premature aging 
and a predisposition to malignant tumours, particularly osteosarcomas (161).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite its long history, only about 300 cases of RTS have been reported in 
the scientific literature thus far (161, 162). Interestingly, mutations in the RECQL4 
gene cause only 60% of all RTS cases (163). Accordingly, RTS seems to be a 
heterogenous disease and mutations in other, yet unidentified gene(s) seem to be 
responsible for the phenotype of the remaining 40% of RTS patients. The number of 
mutations found in RECQL4 is quite low, ranging from nonsense, frameshift and 
Figure 11: Rothmund-Thomson Syndrome Patient 
Depicted is the skin rash (poikiloderma pigmentosum) phenotype, a hallmark of RTS.  
Source: University of Erlangen, Department of Dermatology 
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splice site mutations to intronic insertions and deletions (34). Most of them result in 
premature termination of protein translation and truncated RECQL4 proteins that 
often lack a large part of the helicase domain (164). Cells derived from RTS patients 
show genomic instability, including trisomy, aneuploidy and chromosomal 
rearrangements (161, 165). Additionally, RTS cells are sensitive to ionizing radiation 
and oxidative stress/damage (166, 167). 
 
 
2.4.2 RAPADILINO Syndrome  
 
Another autosomal recessive disease associated with mutations in the RECQL4 
gene is RAPADILINO syndrome (34). The syndrome was originally described in 14 
patients from Finland. To date, additional 3 cases of RAPADILINO syndrome have 
been reported (34). The acronym stands for the characteristic clinical features: 
RAdial hypo-/aplasia, Patellae hypo-/aplasia and cleft or highly arched PAlate, 
DIarrhoea and DIslocated joints, LIttle size and LImb malformation, NOse slender 
and NOrmal intelligence.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: RAPADILINO Syndrome Patient 
This patient is 12 years old. Note the hand and facial features (168). 
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The most common mutations of the RECQL4 gene in RAPADILINO patients 
represent in-frame deletions of exon 7 which do not affect the helicase domain of 
RECQL4 protein (34). Although RAPADILINO patients share some clinical features 
with RTS patients, like photosensitivity with extra pigmentation of skin, or growth 
deficiency, there are unique diagnostic findings such as joint dislocations and patellar 
hypo/aplasia. In contrast to RTS, RADADILINO is more common in females, and only 
7% of the current RAPADILINO patients carry malignant tumors, mainly 
osteosarcomas (169). 
 
 
2.4.3 Baller-Gerold Syndrome  
 
BGS, originally discovered in 1950 (170), is the third recently reported autosomal 
recessive disorder linked to mutations in the RECQL4 gene (35). Approximately 20 
cases of BGS have been reported in the scientific literature thus far (35). The clinical 
hallmarks of BGS are radial aplasia/hypoplasia and craniosynostosis.  
 
 
 
 
 
 
 
 
 
Figure 13: Baller-Gerold Syndrome Patients 
Left picture: First characterization of the clinical phenotype of BGS 1950 (170) 
Right picture: Craniosynostosis phenotype of BGS patient (35) 
 
 
To date, most mutations of RECQL4 found in BGS patients represent a 
R1021W missense mutation and a 2886 delta T frameshift mutation of exon 9. 
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Surprisingly, none of the 24 BGS patients reported so far show any predisposition for 
cancer (35). 
 
 
2.4.4 RECQL4 Mouse Models 
 
In 2002, the Furuichi group created the first RECQL4 knock-out mouse model (171). 
These mice were embryonic lethal, showing severe proliferation defects and 
therefore could not be used as a model for RTS. One year later, the Kito group 
generated another RECQL4 knock-out mouse model by deleting exon 13 of the 
RECQL4 gene, which encodes part of the central RecQ-helicase domain. Exon 13 is 
a hot spot for mutations identified in RTS patients (172). This RECQL4 deficient 
mouse showed severe growth retardation and several tissue abnormalities that 
resemble those of RTS patients. Additionally, the proliferation rate of Mouse 
Embryonic Fibroblasts (MEFs) derived from this RECQL4 deficient mouse was 
decreased. Only 5% of the mutant mice survived the first 14 days, and these mice 
failed to develop poikiloderma and malignancies, both characteristics of RTS (172). 
 One year ago, the Luo group generated the third RECQL4-knock-out mouse 
by deleting the RECQL4 coding region including exons 9-13 (173). 84% of all 
homozygous RECQL4-/- progeny survived to adulthood, with some exhibiting typical 
clinical features of RTS like hypo-/hyper-pigmented skin, skeletal limb defects and 
palatal patterning defects. Furthermore, chromosomal analysis using different cell 
types derived from this RECQL4 deficient mouse displayed an overall aneuploidy 
phenotype and a significant increase in the frequency of premature centromere 
separation, suggesting that this RECQL4-/- mouse is a good model for human RTS 
(173). 
 Taken together, the results derived from the experiments with various 
RECQL4-/-  mice showed that these mice accumulate defects that clearly reflect the 
situation in humans, i.e. different mutations in the RECQL4 gene lead to different 
phenotypes. It would therefore be of particular interest to investigate whether the 
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genotype-phenotype correlations seen in humans could be observed in mice by 
mimicking mutations causing RAPADILINO and BGS syndromes. 
 
 
2.4.5 RECQL4 in the Context of DNA Replication 
 
In the past 2 years, analyses of RECQL4 in Xenopus laevis have indicated an 
interesting novel role for RECQL4 in the initiation of DNA replication. The Xenopus 
laevis RECQL4 protein (xRTS) is 60% identical to human RECQL4 and shares the 
central helicase domain common among all RecQ family members. The N-terminal 
region of xRTS shows 20% identity to two yeast proteins, Sld2 and Drc1, which are 
both required for the establishment of replication forks (174-176). This feature makes 
xRTS unique among the members of the RecQ family. The Venkitaraman lab showed 
that immunodepletion of xRTS from Xenopus laevis egg extracts leads to a reduction 
and delay of sperm chromatin replication, an effect that can be rescued by 
complementing the extracts with the purified recombinant wild-type human RECQL4 
(177). These findings were recently confirmed by the Takisawa group, showing that 
purified N-terminal fragments of xRTS were able to rescue the DNA replication 
activity of RECQL4-depleted extracts (178). Accordingly, by knocking down the 
murine homologue of xRTS with shRNA in primary MEFs, the proliferation rate and 
DNA replication of these primary cells was highly perturbed. Together, these results 
suggest that RECQL4 has a role in DNA replication and that this function is 
conserved during evolution.  
 
 
2.4.6 RECQL4 Interacting Partners 
 
 Several attempts have been made thus far to identify proteins that associate 
with RECQL4 (Fig. 14). Recent studies in the Wang group have revealed that 
RECQL4 isolated from HeLa cells is found in a complex with UBR1 and UBR2 (179). 
These two 200 kDa proteins share high sequence similarities to each other and 
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belong to the family of E3 ubiquitin ligases of the N-end rule pathway, which is part of 
the Ubiquitin-proteasome system (180). The N-end rule pathway exists in all 
organisms examined, from mammals to fungi and bacteria. In eukaryotes it is part of 
the ubiquitin system. By the action of the three ubiquitin-ligases (E1, E2 and E3), a 
substrate protein is polyubiquitylated and subsequently degraded by the 26S 
proteasome (180). Surprisingly, the Wang group found that RECQL4 is not 
ubiquitylated in vivo. In addition, newly synthesized RECQL4 was shown to be a 
stable protein (half-life of 2h) and the level of RECQL4 protein was not increased by 
inhibiting the proteasome with different drugs. Despite these discoveries, the 
functionality of the physical interaction between RECQL4 and UBR1/UBR2 remains 
unknown and further investigations are needed to elucidate a novel function of 
ubiquitin ligases in the maintenance of genome stability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our group found that RECQL4 is in a complex with Rad51 in vivo (181). It has 
been previously reported that Rad51 foci, which are important for DNA repair by 
homologous recombination, accumulate at sites of single stranded DNA after 
Figure 14: RECQL4-interacting partners and their function 
The few interacting partners of RECQL4 identified so far suggest different roles for RECQL4 in DNA 
metabolism   
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induction of DNA double strand breaks (DSB) (182). In response to the induction of 
DSBs by treatment with etoposide, a portion of RECQL4 and Rad51 nuclear foci 
colocalized, suggesting that RECQL4 plays a role in the repair of DSBs by 
homologous recombination (181). The precise role of RECQL4 in DSB repair via its 
interaction with Rad51 is currently being investigated in our lab.  
 Recently, Cut5 was shown to interact with the Xenopus laevis homologue of 
RECQL4 both, in vitro and in vivo (178). Cut5, the metazoan homologue of S. 
cerevisiae Dpb11, is required for the loading of DNA polymerases onto chromatin 
(183, 184). As mentioned above, the N-terminus of RECQL4 has similarity to Sld2 
(“synthetically lethal with dpb11”), one of six Sld family members found to interact 
with Dpb11 (185). Thus, these findings provide an additional hint that RECQL4 may 
function during DNA replication.  
 The Frank group reported the physical interaction between RECQL4 and 
poly(ADP-ribose) polymerase-1 (PARP-1) (186). PARP-1 is involved in different 
pathways of DNA metabolism such as recombination, repair and transcriptional 
regulation (187). Additionally, PARP-1 is part of the base excision repair (BER) 
pathway and is activated in response to DNA breaks (188). The authors showed 
complex formation between RECQL4 and PARP-1 in vitro and in vivo. Additionally, 
PARP-1 was able to poly(ADP-ribosyl)ate RECQL4 in vitro (186). However, the 
functional relevance of this posttranslational modification of RECQL4 has to be 
confirmed by further in vitro and in vivo experiments. 
 In summary, the current data from several different protein interaction assays 
indicate that RECQL4 is involved in DNA repair and replication processes. However, 
further studies are needed to identify additional RECQL4-interacting proteins in order 
to draw a more precise picture of the exact cellular pathways RECQL4 might be 
involved in. The extended N- and C-terminal domains of all RecQ helicases studied 
so far show very little sequence identity and are therefore thought to confer specificity 
to these proteins by mediating protein-protein interactions (23). For this reason, N- 
and C-terminal fragments of RECQL4 could be used as baits in a yeast two-hybrid 
screen in order to find novel RECQL4 interacting partners. On the other hand, 
different RECQL4 specific antibodies have been raised in the last couple of years 
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that could be used to co-immunprecipitate RECQL4-interacting partners from 
mammalian cells extracts, followed by mass spectrometry analysis. 
 
 
2.4.7 Subcellular Localization of RECQL4 
 
Four different groups have thus far examined the subcellular localization of RECQL4 
in different mammalian cells and their observations are contradictory. The Furuichi 
group overexpressed full length FLAG-tagged RECQL4 in HeLa cells and 
immunfluorescence analysis suggested RECQL4 is localized exclusively to the 
nucleus (163). In 2004, the Wang group extensively studied the subcellular 
localization of RECQL4 using different cell types and three polyclonal anti-RECQL4 
antibodies (179). Western blot analysis of HeLa, MCF7 and Jurkat cell extracts 
revealed that RECQL4 was found predominantly in the cytoplasm, while indirect 
immunfluorescence experiments using HeLa cells displayed RECQL4 localization to 
both the nucleus and the cytoplasm. In contrast, RECQL4 was largely present in the 
nuclear fraction derived from untransformed WI-38 fibroblasts.  
 Our group raised two antibodies, against the N- and C-termini of RECQL4, and 
used them in immunofluorescence experiments on several exponentially growing 
human cell lines. Although we found that the majority of RECQL4 protein is detected 
in the nucleus, a small amount of it was found in the cytosolic fraction of HeLa cell 
extracts (181). Furthermore, we found that endogenous RECQL4 localized 
exclusively in discrete nuclear foci in HeLa, WI-38/VA13 and primary skin fibroblast 
cells, and that the number of these does not significantly change during the cell cycle 
or upon the induction of DNA DSBs. In addition, we found that RECQL4 foci partially 
coincide with those formed by promyelotic leukemia (PML) bodies and Rad51 as well 
as with regions of single-stranded DNA (ssDNA) upon induction of DSBs. PML 
bodies and Rad51 foci have been shown to regulate the response to and repair of 
DSBs (58, 189). These findings suggested a role for RECQL4 in the repair of DSBs 
by homologous recombination (HR) and indicated a completely novel function for 
RECQL4 in human cells (181). 
 33 
 Very recently, the Frank group investigated the localization of RECQL4 in 
living cells by fusing EGFP to the N-terminus of the RECQL4 sequence (186). 
RECQL4 displayed nucleoplasmic staining in most of the cells examined and no 
significant cytoplasmic staining was observed. Using different EGFP deletion mutants 
of RECQL4 the authors further characterized the domain structure. Their data 
suggests that RECQL4 contains at least two N-terminal nuclear localization signals 
(NLS) and one nucleolar localization signal (NOS) spanning amino acids 376-386. 
Furthermore, RECQL4 nucleolar enrichment was observed after treating cells with 
H2O2 or streptonigrin which leads to oxidative damage of DNA. Interestingly, RECQL4 
localization did not change after treating cells with other DNA damage agents such 
as γ irradiation, etoposide, bleomycin, or UV irradiation (186). 
 
 
2.4.8 Biochemical Properties of the RECQL4 Protein 
 
 Compared to all other human RecQ family members, the biochemical 
properties of the RECQL4 protein are thus far only poorly understood. This is mainly 
due to the inability to purify the RECQL4 protein. Many groups including ours have 
attempted to purify full-length RECQL4 protein using different expression systems but 
all efforts resulted in production of truncated RECQL4 protein. Consequently, the first 
enzymatic activity assays were performed by the Wang group with 
immunoprecipitated RECQL4 protein from HeLa cell extracts (179). RECQL4 coupled 
to protein-A sepharose beads showed DNA dependent ATPase activity, however, 
RECQL4 failed to unwind any of the tested DNA substrates, although BLM helicase 
purified by the same way possessed DNA helicase and translocase activity.  
 One year ago, the Sung group purified full-length RECQL4 protein from E.coli 
(190). Although the yield of purified RECQL4 protein was low, the authors 
demonstrated that RECQL4 has no detectable helicase activity, but possesses 
ssDNA-stimulated ATPase activity. In addition, the authors showed that RECQL4 
binds to ssDNA, an effect that could be inhibited by ssDNA binding protein RPA 
(190). 
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 Taken together, the current studies indicate that RECQL4 is not an active 
helicase, however, it still remains possible that RECQL4 needs a co-activator 
protein(s) and/or a particular post-translational modification(s) in order to accomplish 
a DNA unwinding function. To this end, it would be interesting to test if RECQL4 
purified from mammalian or insect cells possesses helicase activity. 
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2.5 RECQL5 
 
 
2.5.1 General Information 
 
As with RECQL1, no human genetic disease has been linked to a deficiency in the 
RECQL5 gene. The RECQL5 gene is located on chromosome 17q25.2. The 19 
exons of the human RECQL5 gene give rise to alternatively spliced mRNA species 
which encode the three designated RecQL5α, RecQL5β and RecQL5γ isoforms. 
They have predicted molecular masses of 46 kDa, 108.9 kDa and 49 kDa 
respectively (191). The different RecQL5 isoforms seem to be expressed ubiquitously 
in human tissues, with a very high abundance in the testis. Their subcellular 
localization has been studied using ectopically expressed proteins. The small 
isoforms, RecQL5α and RecQL5γ, are entirely cytoplasmic, while RecQL5β is 
transported to the nucleus, consistent with the presence of a putative NLS (192). All 
biochemical and cell biological studies to date have been performed with the largest 
isoform RECQL5β. 
 
 
2.5.2 Biochemical Properties of the RECQL5β Protein 
 
Garcia et al. described the first biochemical properties of the human RECQL5β in 
2004 (193). Like BLM and WRN, RECQL5β was shown to be an ATP-dependent 3’-
5’ DNA helicase that can promote migration of Holliday junctions. RECQL5β required 
the single-stranded DNA-binding protein RPA in order to mediate unwinding of DNA 
substrates. In contrast to BLM and WRN that form oligomeric structures (194, 195), 
the RECQL5β helicase exists as a monomer. The most important finding, which has 
been confirmed for all human RecQ helicases is that RECQL5β exhibits an efficient 
DNA strand annealing activity, residing in the C-terminal half of the protein (193).  
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Furthermore, RECQL5β helicase possesses the ability to promote strand exchange 
on synthetic forked DNA structures that mimic a stalled replication fork (196).  
 
 
2.5.3 RECQ5Lβ Interacting Proteins 
 
Immunoprecipitation and co-localization studies revealed that RECQL5β is found in 
complex with topoisomerase 3α and 3β (192), suggesting a specific role for 
RECQL5β in DNA metabolism.  
 Recent findings indicate physical interaction of RECQL5β and PCNA in human 
cells (196). RECQL5β and PCNA co-localize in distinct DNA replication foci in S 
phase nuclei, suggesting a role in regression of stalled replication forks in vivo (Fig. 
15).   
 
 
 
 
 
 
 
 
 
 
 
Figure 15: RECQL5β-interacting partners and their function 
The cellular role of RECQL5β remains to be elucidated 
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3 Posttranslational Modifications of Proteins 
 
 
3.1 General Introduction  
 
At the time when the human genome was sequenced, researchers were surprised that 
it only contained approximately 30,000 genes and not 100,000 as had been predicted. 
It became more and more clear, that evolution had favored the existence of a limited 
number of genes with inducible functions over the existence of multiple genes with very 
specific functions. A large number of gene products are posttranslationally modified, 
therefore fine-tuning the roles of the corresponding proteins. The ensemble of covalent 
changes are termed post translational modifications to reflect that these changes are 
introduced after translation of mRNA nucleotide sequences into amino acid-based 
protein sequences at ribosomes (197). Posttranslational modifications can be divided 
into two broad categories. The first is the covalent addition of one or more groups, such 
as phosphoryl, acetyl, or glycosyl, to amino acid side chains of proteins. The second 
category is the hydrolytic cleavage of peptide bonds by proteases. 
 It has been estimated that about 5% of the human genome codes for enzymes 
that are involved in the posttranslational modification of target proteins. 
Posttranslational modifications can influence protein stability, protein-protein 
interactions, protein-DNA interactions, catalytic activities, and protein localization.  
In the following section, I will exclusively focus on the acetylation of target proteins by 
different acetyltransferases and the functional consequences of this specific 
posttranslational modification. 
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3.2 Protein Acetylation 
 
 
3.2.1 Reversible Nε- Acetylation of Lysine Residues 
 
Protein acetylation is a widely used mechanism in eukaryotes. The irreversible 
Nα-terminal acetylation occurs co-translationally and is one of the most abundant 
eukaryotic protein modifications with 85% of all proteins being modified (198). In 
addition, proteins can be acetylated on their Nε-lysine (199) and two basic enzymatic 
mechanisms are known to be used by lysine acetyltransferases in order to add an 
acetyl group to the Nε-lysine of substrate proteins (Fig. 16).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Two distinct enzymatic mechanisms used for acetylation 
(a) Acetylation by direct transfer mechanism. (b) Acetylation by ping-pong mechanism. (Adapted from 
(200)) 
 
 
The first mechanism involves the formation of a tertiary complex composed of the 
enzyme, acetyl coenzyme A (Ac-CoA) and the protein substrate. The enzyme bound 
Ac-CoA binds a protein substrate and positions one of the lysine residues of the 
substrate for nucleophilic attack of Ac-CoA. The modified substrate is released 
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followed by release of CoA (Fig. 16a). The second mechanism is a ping-pong 
mechanism, used by the p300 family of acetyltransferases (discussed in section XY). 
Ac-CoA binds and is attacked by a catalytic residue of the enzyme, resulting in the 
formation of a covalent acetyl-enzyme intermediate, while CoA is released. In a second 
step, the substrate protein binds to coordinate a nucleophilic attack by a lysine residue 
on the acetyl-enzyme intermediate. The acetyl group is transferred and the modified 
substrate is released (Fig. 16b). 
 Unlike Nα-terminal acetylation, Nε-acetylation is a reversible process providing 
dynamic responses to extra- and intracellular signaling events. The proteins involved in 
the opposing reactions are the histone deacetylases (HDACs), they are able to remove 
the acetyl group from the lysine residue reestablishing the positive charge.  
 
 
3.2.2 Acetylation of Serine and Threonine Residues 
 
Recent studies by Mukherjee et al. identified serine and threonine as new targets for 
acetlytransferase mediated acetylation (200). The authors determined the mechanism 
by which the bacterium Yersinia prevents the activation of mitogen-activated protein 
kinase (MAPK) and the nuclear factor kappaB (NFkappaB) signaling pathway in host 
cells. They showed that YopJ, one of six bacterial effectors secreted into the host cell, 
acts as an acetyltransferase, using acetyl-coenzyme A (CoA) to modify critical serine 
and threonine residues in the activation loop of MAPKK6 thereby blocking its 
phosphorylation. The acetylation on MAPKK6 directly competed with phosphorylation, 
preventing activation of the modified protein. It will be of particular interest to further 
elucidate if this covalent modification may be used as a general regulatory mechanism 
in biological signaling. 
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3.2.3 Acetylation of Histones 
 
More than 40 years ago histones derived from calf thymus were reported to be 
acetylated in vivo (201). Originally, histone acetylation was associated with highly 
active transcription, while silent regions appeared to be hypoacetylated (202, 203). 
Acetylation neutralizes the positive charge of the lysine residue side chains and it was 
suggested that the interaction with the negatively charged sugar-phosphate backbone 
of the DNA is weakened, thus negatively influencing the nucleosomal stability and 
facilitating transcription. Acetylated histone N-terminal tails influence transcription on 
two levels i) by inducing chromatin structure changes and subsequent accessibility and 
ii) by serving as interaction platforms for specific protein modules (bromo domains). 
 However, it’s inexpedient to focus on the acetylation of histones and subsequent 
functional consequences without a more global view of histone modifications. In the 
last couple of years it has been shown that histones are targets for extensive 
posttranslational modifications such as phosphorylation, methylation, ubiquitination, 
SUMOylation, and acetylation (204). These modifications decorate the canonical 
histones (H2A, H2B, H3 and H4), as well as variant histones (such as H3.1, H3.3 and 
HTZ.1). Most modifications take place at the amino- and carboxy-terminal histone tails, 
and only a few localize to the histone globular domains. Some of the functional 
outcomes of these modifications are clear. For example, there is abundant evidence 
that acetylation is activating, whereas SUMOylation seems to be repressing 
transcription, and these two types of modification may mutually interfere. On the other 
hand, methylation and ubiquitylation have variable effects, depending on the precise 
residues and contexts (Table 1). 
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 Table 1: A list of histone modifications and their role in transcription 
 
 
 
 
 
 
 
 
 
 
 
 
 
             (Adapted from (205)) 
  
 Accordingly, transcriptional regulation is much more complex than just static 
on/off switches and more work has to be done in order to understand the nuanced 
chromatin ‘language’. For more detailed information see (205). 
 
 
3.2.4 Histone Acetyltransferases 
 
Histone acetyltransferases (HATs) can be divided into two groups; the B-type HATs 
that are found in the cytoplasm and the nuclear A-type HATs. In 1995, S. cerevisiae 
Hat1 was the first HAT identified (206). Hat1 was shown to be a B-type HAT, involved 
in the acetylation of soluble but not nucleosomal histones in the cytoplasm that are 
subsequently incorporated into chromatin during replication (207). One year later, the 
first A-type HAT was identified in the ciliate Tetrahymena thermophila showing strong 
sequence homologies to the yeast transcriptional co-activator GCN5 (General control 
non-derepressible-5) (208). This discovery provided the first molecular evidence for a 
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direct link between histone acetylation and transcriptional regulation. This concept 
received rapid experimental support through the identification of several other 
adaptor/coactivator proteins with intrinsic HAT activity, including mammalian GCN5 
(209-211) and its ortholog, PCAF (211), CREB-binding protein (CBP) (212, 213), p300 
(213), and TAFII250 (214, 215). Table 2 gives an overview of the different HATs and 
their potential functions. Recent studies show that some HATs have factor 
acetyltransferase (FAT) activity. FAT activity has been demonstrated for the histone 
acetyltransferases p300/CBP, PCAF and TAFII250 with substrates ranging from 
transcriptional activators and basal transcription factors to non-histone chromosomal 
proteins and different DNA repair factors (216). The section below will concentrate on 
p300, which is the relevant acetyltransferase for this thesis.  
 
 
 
 
Table 2: A list of histone acetyltransferase 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         (Adapted from (217)) 
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3.2.5 Histone Deacetylases 
 
Acetylated lysine residues are deacetylated by a specific class of enzymes called 
histone deacetylases (HDACs). In the same year that the first HAT was identified as 
transcriptional coactivator Schreiber’s group purified and cloned human HDAC1 (218). 
Based on sequence homologies to yeast proteins, human histone deacetylases 
(HDACs) are subdivided into four classes (217) (Table 3). Class I HDACs display 
sequence homology to yeast Rpd3, which deacetylates all four core histones (HDAC1, 
2, 3 and 8). Class II HDACs (HDAC 4, 5, 6, 7, 9 and 10) are similar to yeast Hda1, 
which deacetylates histones H2B and H3 (219). The activities of the members of 
classes I and II are Zn2+-dependent. Class III HDACs (SIRT1-7) are (NAD+)-dependent 
and are related to yeast Sir2, which is involved in the regulation of gene silencing and 
aging (220). Class IV consists of the recently identified HDAC11 (221). Structurally 
HDAC11 is most closely related to the class I HDACs. 
 
 
       Table 3: A list of histone deacetylases 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              (Adapted from (217)) 
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 Transcriptional repression is either achieved by the sequestring of 
transcriptional activators or by occupancy of enhancer binding sites and does not 
require enzymatic activity (222). Furthermore, HDACs are active repressors and 
remove the acetyl group from lysine residues. Mutations in their conserved catalytic 
domain release the repressive effect of HDACs (223). 
 Surprisingly, it was shown that HDACs can also function as transcriptional 
activators. Deletion of Rpd3 or Hda1 in yeast negatively effected the transcription of 
certain genes and increased gene silencing (224).  
  These finding provide evidence that the regulation of transcription by 
acetylation is a complex and dynamic process. 
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3.3 Histone Acetyltransferase p300/CBP 
 
 
3.3.1 Structure and Function of p300/CBP 
 
 p300 and its homologue CBP are present in many multicellular organisms, 
including flies, worms and plants, but not in lower eukaryotes such as yeast (225-227). 
In the last decade, they have been the most studied HATs in the context of 
transcriptional regulation. Originally isolated as adenoviral E1A interacting (228) and 
CREB interacting protein (cAMP-response-element-binding protein) (229), p300 and 
CBP function as global transcriptional co-activators for more than 40 different 
transcription factors, supporting their role as key players in different signaling pathways 
(230). 
  As depicted in Figure 17, p300 and CBP share several conserved regions, 
including three cysteine-histidine rich regions CH (CH1, -2, and -3), the binding site for 
the CREB transcription factor, referred to as the KIX domain, the bromodomain 
important for the binding of acetylated lysines (BD), the HAT domain and the steroid 
receptor coactivator-1 interaction domain (SID). CBP and p300 interact directly with the 
basal transcription factors TATA-binding protein (TBP) (231), TFIIB (231, 232) and 
TFIID (233) and form a complex with RNA polymerase II (234-237). Additionally, CBP 
and p300 can bind to a variety of diverse transcription factors and other proteins, 
through their CH-1, CH-3, KIX and SID domains (238, 239). 
 
 
 
 
 
 
One important cellular role of p300/CBP is to work as “molecular bridges” mediating 
and stabilising the interaction between sequence-specific transcription factors and the 
Figure 17: Schematic representation of the p300/CBP gene 
Colored boxes represent shared conserved regions important for protein- and DNA interactions. 
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RNA polymerase II transcription machinery (238). The second important aspect of the 
coactivator function of p300/CBP is their ability to serve as ‘protein scaffolds’ for the 
assembly of other chromatin modifying and remodelling complexes. The interaction 
with other HATs such as SRC-1 (240, 241), P/CAF (213) and SRC-3 (ACTR) (242) has 
been described. Protein scaffolds increase the local concentration of cofactors around 
the transcription start sites facilitating protein-protein and protein-DNA interactions.  
 Thirdly, p300 and CBP acetylate promoter proximal nucleosomal histones, 
resulting in increased accessibility of the DNA for other essential regulators (212, 213, 
243). Soon after the discovery of their enzymatic activities the first non-histone protein 
(p53) was reported to be acetylated by p300 (244). The increasing number of non-
histone proteins acetylated by p300 and CBP is discussed in further detail in section 
3.3.3 
 
 
3.3.2 p300/CBP and Human Disease 
 
The importance of CBP and p300 is supported by evidence that genetic alterations in 
their genes and subsequent functional inactivation of the proteins are associated with 
human disease (245-247). Mutation of one copy of the CBP gene results in a 
congenital developmental disorder called Rubenstein-Taybi-Syndrome (RTS), which is 
characterized by retarded growth and mental function, broad thumbs and typical facial 
abnormalities (248). Furthermore, RTS patients have an increased tumor risk (249). 
 Heterozygous chromosomal translocations involving CBP or p300 are found in 
patients suffering from acute myeloid leukaemia (ALM) (250). In addition, heterozygous 
mutations in the p300 gene have been detected in primary solid tumors and tumor cell 
lines, mainly of epithelial origin (251-254). Most of the mutations lead to truncated p300 
protein and in the majority of the cases the second allele was inactivated through 
deletion (loss of heterozygosity), silencing (hemizygosity), or a different mutation 
(compound heterozygosity), qualifying p300 as a classical tumor suppressor gene, 
according to Knudson’s two-hit model (255). 
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In summary, findings on CBP and p300 in human disease indicated that the dosage of 
these proteins is essential in the regulation of normal differentiation, growth control and 
homeostasis in humans. 
 
 
3.3.3 p300/CBP Acetylation of Target Proteins 
 
 In 1996, Ogryzko et al. demonstrated that p300/CBP was not only a 
transcriptional adaptor but also a histone acetyltransferase, acetylating all four histones 
in nucleosomes (213). Two years later, Schiltz et al. described that the preferred p300 
in vitro sites of acetylation on the N-terminal histone tails are lysine 12 (K12) and K15 
in histone H2B, K14 and K18 in histone H3 and K5 and K8 in histone H4 (256).  
 In addition to their ability to acetylate histones, CPB and p300 have also been 
shown to acetylate a variety of other proteins and have therefore been called factor 
acetyltransferases (FAT) (216, 250). The list of acetylated non-histone proteins 
involved in transcription, including site-specific transcription factors, general 
transcription factors, cofactors and chromatin remodellers grew exponentially. A 
selection of these acetylation target proteins will be discussed. 
 In 1997, Gu and co-workers identified the tumor suppressor p53 as the first non-
histone acetylation target of p300 (244). p53 was found to be acetylated in vitro and in 
vivo on its C-terminal domain known to be critical for the regulation of DNA binding. 
The acetylation of p53 dramatically stimulated its sequence-specific DNA-binding 
activity, thus positively influencing p53 transcriptional activation activity. 
 Some acetylated non-histone proteins are important for DNA repair such as the 
flap endonuclease 1 (Fen1) (257). Hasan et al. demonstrated that the DNA binding and 
endonuclease activity of Fen1 was reduced upon acetylation by p300. The same 
authors could also identify polymerase β (pol β) as a non-histone acetylation target of 
p300. p300 and pol β co-localize and physically interact in human cells. Acetylated Pol 
β showed an impaired AP lyase activity essential for proper base excision repair (258).  
 Acetylation of the thymine DNA glycosylase (TDG) by p300/CBP did not affect 
the TDG DNA cleavage activity but released CBP from the DNA bound complex and 
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abolished interaction with the AP-endonuclease (259). Additionally, acetylation of 
human DNA glycosylase NEIL2 on lysine 49 inhibited the base excision as well as the 
AP lyase activity of NEIL2 and extended the list of modified repair proteins (260). 
 Acetylation of non-histone substrates can result in either positive or negative 
effects on transcription by affecting, for example, protein–protein interactions (e.g. the 
activator of thyroid and retinoid receptors ACTR (261)), protein–DNA interactions (e.g. 
the high mobility group protein HMGI(Y) (262)), or protein half-life (e.g. E2F (263)). 
 Recently, protein acetylation has been proposed as a new mechanism for 
modulating subcellular localization (131, 264-270). Acetylation target lysine residues 
that are located in the nuclear localization signal (NLS) of several proteins. This can 
directly modulate NLS function (265) and disrupt its association with the import 
machinery leading to cytoplasmic localization of proteins (267). Alternatively, 
acetylation inside NLSs, rather than affecting the NLS function itself, can cause a 
conformational change that impairs the function of the nuclear export signal (NES), 
promoting protein accumulation in the nucleus (131, 267, 269). 
 Taken together, protein acetylation seems to be a widespread mechanism to 
control a variety of different cellular mechanisms. 
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4 Results 
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RECQL4 is a member of the conserved 
RecQ family of DNA helicases that play 
important roles in the maintenance of genome 
stability in all organisms examined. Although it 
was reported that genetic alterations in the 
RECQL4 gene are associated with three 
autosomal recessive disorders called Rothmund-
Thomson, RAPADILINO, and Baller-Gerold 
syndromes, respectively, the molecular role of 
RECQL4 still remains poorly understood. Here 
we show that RECQL4 specifically interacts 
with the histone acetyltransferase p300 both, in 
vivo and in vitro, and that p300 acetylates one or 
more of the lysine residues at positions 376, 380, 
382, 385, and 386 of RECQL4. Furthermore, we 
report that these five lysine residues lie in a 
short motif of 30 amino acids that is essential for 
the nuclear localization of RECQL4. 
Remarkably, the acetylation of RECQL4 by 
p300 in vivo leads to a significant shift of a 
proportion of RECQL4 protein from the nucleus 
to the cytoplasm. Lastly, we demonstrate that 
p300 stimulates the ATPase activity of RECQL4 
in vitro. Our results provide first evidence of a 
post-translational modification of the RECQL4 
protein and suggest that acetylation of RECQL4 
by p300 regulates the trafficking of RECQL4 
between the nucleus and the cytoplasm. 
 
Genome instability plays a major role in 
the development and progression of cancer. All 
organisms have developed pathways to mitigate 
DNA damage by employing enzymes involved in 
all DNA metabolic processes including replication, 
recombination, and repair (1). The fundamental 
importance of these enzymes, such as DNA 
helicases and acetyltransferases, is highlighted by 
the variety of genetic instability disorders arising 
from enzymes defective in these functions (2, 3). 
One family of proteins required to 
maintain genome stability is the RecQ helicase 
family (4).  Humans possess five RecQ 
homologues: RECQL1, BLM, WRN, RECQL4, and 
RECQL5. Five autosomal recessive disorders, 
characterized by genomic instability, cancer 
progression, and developmental abnormalities, have 
been associated with defects in the BLM (Bloom 
syndrome) (5), WRN (Werner syndrome) (6), and 
RECQL4 (Rothmund-Thomson (RTS), 
RAPADILINO, and Baller-Gerold syndromes 
(BGS) (7-10) gene products. RTS is an unusual 
autosomal recessive condition associated with 
poikiloderma, growth deficiency, juvenile cataracts, 
premature aging and a predisposition to malignant 
tumours, particularly osteosarcomas (11). 
Interestingly, mutations in the RECQL4 gene cause 
only 60% of all RTS cases (12). Accordingly, RTS 
seems to be a heterogenous disease and mutations 
in other, yet unidentified gene(s) seem to be 
responsible for the phenotype of the remaining 40% 
of RTS patients. The number of mutations found in 
RECQL4 is quite low, ranging from nonsense, 
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frameshift, and splice site mutations to intronic 
insertions and deletions (8). Most of them result in 
premature termination of protein translation 
yielding truncated RECQL4 proteins that often lack 
a large part of the helicase domain (13). Cells 
derived from RTS patients show genomic 
instability, including trisomy, aneuploidy and 
chromosomal rearrangements (11, 14). 
Additionally, RTS cells are sensitive to ionizing 
radiation and oxidative stress (15, 16).  
RAPADILINO syndrome is another 
autosomal recessive disease associated with 
mutations in the RECQL4 gene (8). The acronym 
stands for the characteristic clinical features: 
RAdial hypo-/aplasia, Patellae hypo-/aplasia and 
cleft or highly arched PAlate, DIarrhoea and 
DIslocated joints, LIttle size and LImb 
malformation, NOse slender and NOrmal 
intelligence. The most common mutations of the 
RECQL4 gene in RAPADILINO patients represent 
in-frame deletions of exon 7 which do not affect the 
helicase domain of RECQL4 protein (8). Although 
RAPADILINO patients share some clinical features 
with RTS patients, like photosensitivity with extra 
pigmentation of skin and growth deficiency, there 
are unique diagnostic findings such as joint 
dislocations and patellar hypo/aplasia. In contrast to 
RTS, RADADILINO syndrome is more common in 
females, and only 7% of the current RAPADILINO 
patients developed malignant tumors, mainly 
osteosarcomas (17). 
BGS is the third recently reported 
autosomal recessive disorder linked to mutations in 
the RECQL4 gene (7). The clinical hallmarks of 
BGS are radial aplasia/hypoplasia and 
craniosynostosis. To date, most mutations of 
RECQL4 found in BGS patients represent a 
R1021W missense mutation and a 2886 delta T 
frameshift mutation of exon 9. Surprisingly, none 
of the 24 BGS patients reported so far show any 
predisposition for cancer (7). Furthermore, the 
results derived from the experiments with various 
RECQL4-/- mice showed that these mice accumulate 
defects that clearly reflect the situation in humans, 
i.e. different mutations in the RECQL4 gene lead to 
different phenotypes (18-20). 
 Thus, the cumulative set of data suggests 
that RECQL4 has roles independent of the helicase 
domain. Whether the role of the RECQL4 N-
terminal domain is independent of the helicase 
domain, or if it is sufficient to perform a partial 
function remains to be elucidated in future 
experiments. 
While the distinct molecular functions of 
BLM and WRN helicases have been widely 
characterized in the last decade, the precise 
molecular and cellular role of the RECQL4 protein 
has not yet been elucidated. Recent studies revealed 
 an involvement of RECQL4 protein in 
DNA replication (21, 22) and repair of DNA double 
strand breaks (DSB) by homologous recombination 
(HR) (23, 24). The localization of RECQL4 in 
different mammalian cells has been studied 
extensively (9, 23, 25-27). Several cell biological 
and biochemical studies indicated that RECQL4 
can be found both in the nucleus and cytosol of 
different transformed cell lines (23, 27). In the 
nucleus, RECQL4 forms discrete nuclear foci in 
response to DNA damage that coincide with those 
formed by promyelocytic leukaemia (PML) bodies 
and Rad51, further suggesting a role in DNA DSB 
repair by HR (23). Furthermore, upon oxidative 
damage, RECQL4 moves to the nucleolus in living 
HeLa cells and the nucleolar localization signal 
(NOS) was mapped to amino acids (aa) 376-386 in 
the RECQL4 sequence (26). Recent findings 
indicated that RECQL4 aa 363-492 are important 
for the nuclear import and localization of RECQL4 
protein in different mammalian cells, while aa 420-
463 encoded by exon 7 are crucial for its retention 
in the nucleus (25). In the cytosol, RECQL4 forms 
stable complexes with cytosolic ubiquitin ligases 
UBR1 and UBR2, which function in the N-end rule 
pathway (27). However, the exact mechanism of 
how RECQL4 is transported from the nucleus to 
the cytosol as well as what the function of the 
cytosolic RECQL4 protein is, remains totally 
unexplored. 
Another class of enzymes, known as 
acetyltransferases, are also responsible for 
maintaining genome stability (28, 29). Histone 
acetyltranferases (HATs) catalyze a reversible 
transfer of an acetyl group from acetyl-coenzyme A 
to ε-NH3+ of lysine residues on core histone tails 
(30). Traditionally, HATs have been associated 
exclusively with the acetylation of histone tails and 
transcriptional regulation through chromatin 
remodelling. By alleviating repressive histone-
DNA binding, and thus facilitating the association 
of transcription factors with DNA, histone 
acetylation can lead to increased transcriptional 
activity (31). One such HAT is p300/CBP which 
includes two distinct but related proteins p300 and 
CBP, and participates in many physiological 
processes, including proliferation, differentiation, 
and apoptosis (32). Although p300/CBP was 
originally identified as acetylating lysine residues 
on core histones (33, 34), in the past decade a 
growing body of evidence suggested that other non-
histone targets, including proteins involved in the 
regulation of transcription such as p53, E2F1, 
EKLF, TFIIEβ, TFIIF, TCF, GATA1, HMGI(Y) 
and ACTR (35) as well as DNA repair/replication 
proteins such as PCNA (36), FEN-1 (37), TDG 
(38), APE1 (39), NEIL2 (40), DNA polymerase β 
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 (41), and human 8-oxoguanine-DNA 
glycosylase (OGG1) (42) are also acetylated by 
p300/CBP. Acetylation by p300/CBP can modulate 
the activity of DNA repair/replication proteins 
either positively or negatively. For example, 
acetylation of FEN1 by p300/CBP reduces the 
nuclease activity of FEN1 presumably as a result of 
the reduced DNA binding (37). On the other hand, 
acetylation of TDG by p300/CBP does not affect its 
DNA glycosylase activity, which is stimulated by 
sumoylation, another covalent post-translational 
modification (43). Furthermore, acetylation of 
NEIL2, an oxidized pyrimidine-specific DNA 
glycosylase, was shown to inhibit its enzymatic 
activity (40) whereas acetylation of human OGG1 
by p300/CBP significantly increases OGG1’s 
activity in vitro in the presence of AP-endonuclease 
by reducing its affinity for the abasic (AP) site 
product (42). All these examples highlight the 
importance of p300/CBP in the DNA base excision 
repair process. 
In spite of several recent studies showing altered 
DNA repair and substrate specificity of DNA 
repair/replication proteins due to acetylation by 
p300/CBP, acetylation of RECQL4 as well as its 
physiological relevance has not been addressed so 
far. In this paper, we report the physical and 
functional interaction between RECQL4 and p300. 
Overexpression of p300, but not the catalytic dead 
mutant (p300 ∆HAT), leads to a significant 
translocation of a proportion of RECQL4 protein 
from the nucleus to the cytoplasm. The same effect 
can be observed by treating the cells with histone 
deacetylase (HDAC) inhibitors TSA and 
nicotinamide, suggesting that indeed, acetylation of 
RECQL4 by p300 is involved in the translocation 
of RECQL4 towards the cytoplasm. p300 
specifically acetylates RECQL4 on a stretch of 
Lysine residues, previously shown to function as 
NOS/NLS sequence of RECQL4 (25, 26). 
Furthermore, we demonstrate that mutation of these 
lysine residues to alanine (Lys 376, 380, 382, 385, 
386 Ala), but not to arginine (Lys 376, 380, 382, 
385, 386 Arg), completely abolishes the nuclear 
import of RECQL4 in human cells. Additionally, 
the fusion of the RECQL4 aa 376-386 to the N-
terminus of β-Galactosidase leads to the nuclear 
import of this 100kDa protein in mammalian cells, 
indicating the importance of the positively charged 
amino acid residues for the nuclear import of the 
RECQL4 protein. Lastly, we show that p300 has a 
stimulatory effect on the RECQL4 ATPase activity 
in vitro. Taken together, our data help to understand 
the mechanism by which RECQL4 is translocated 
from the nucleus to the cytoplasm in mammalian 
cells.  
 
 
 
 
 
MATERIALS AND METHODS 
  
Expression and purification of p300- and 
RECQL4 GST fragments in E.coli  
All p300 and RECQL4 protein fragments were 
expressed in E. coli [HMS174(DE3) for p300, 
BL21(DE3) for RECQL4; Novagen] as N-terminal 
fusions with glutathione-S-transferase (GST), using 
the plasmid vector pGEX-6P2 (GE Healthcare) 
with the isopropyl-β-D-thiogalactoside (IPTG)-
inducible T7 promoter. Overnight cultures grown in 
Luria Broth at 37°C were diluted 1:100 into fresh 
medium and incubated until OD600 reached 0.6. 
IPTG was added to 0.5mM, and the cultures were 
incubated at 15°C for 20h. Cells were harvested by 
centrifugation and re-suspended in buffer A (50 
mM Tris, 50 mM NaCl, 20% glycerol, pH 8.0 
supplemented with 1µg/ml bestatin, leupeptin and 
pepstatin protease inhibitors) and stored at -20°C 
overnight (>12h). All subsequent steps were 
performed at 4°C or on ice. Following sonication (8 
× 15s bursts with 5s cooling), lysates were clarified 
by centrifugation (50,000 × g for 45 min) and 
added to glutathione Sepharose 4B beads (GE 
Healthcare). After washing with 20 mM KH2PO4, 
140 mM NaCl, 0.2% [v/v] Triton X-100, pH 8.0, 
bound proteins were eluted in buffer A containing 
10 mM glutathione. Proteins were dialyzed 
overnight against buffer B (20 mM Tris, 200 mM 
NaCl, 1mM EDTA, 0.5% [v/v] NP40, 0.5% [v/v] 
PMSF, 20% [v/v] glycerol) and stored at -80°C. 
 
 
 
Purification of RECQL4 
The human RecQL4 cDNA was cloned into 
pET21b vector (Novagen). The  cDNA of GST was 
cut from pET41a vector (Novagen) and cloned N-
terminally of the RecQL4 cDNA in pET21b. 
RECQL4 protein was expressed in 
BL21(DE3)Rosetta-pLysS cells. Overnight cultures 
grown in Luria Broth at 37°C were diluted 1:100 
into fresh medium and incubated until OD600 
reached 0.4. IPTG was added to 0.3 mM, and the 
cultures were incubated at 18°C for 22h. Cells from 
12 liters of culture were harvested by 
centrifugation, and pellet was resuspended on ice in 
300 ml of  NiLB (pH 8.1, 10 mM Tris-HCl, 30 mM 
KH2PO4, 0.5 M NaCl, 20 mM imidazole 
supplemented with 1 mM PMSF and 2 µg/ml of 
each bestatin, leupeptin and pepstatin). Cells were 
lysed by French press (2x) and sonication. After 
centrifugation (20,000 rpm, 2 hours, +4° C, SS-34 
rotor), the supernatant was loaded on a 1 ml 
HisHiTrap (GE Healthcare) column. The Column  
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was washed by 100 ml NiLB, 30 ml NiLB 
containing 1 M NaCl, 30 ml NiLB with 1 % 
TritonX-100, 30 ml NiLB with 60 mM imidazole. 
Protein was eluted by 300 mM imidazole in NiLB 
containing 10% glycerol. RECQL4 protein 
containing fractions were pooled, desalted to 
GSTLB (GST-loading buffer, pH 7.4, containing 30 
mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 10 % 
glycerol, supplemented with 0.5 mM PMSF and 1 
µg/ml of each bestatin, leupeptin and pepstatin) 
using a 5 ml desalting column (GE Healthcare) and 
applied to 1 ml GST-Sepharose HiTrap column. 
After washing with 50 ml GSTLB containing 0.2% 
Triton X-100, bound protein was eluted by GSTEB 
(GST-elution buffer, pH 8.1 containing 50 mM 
Tris-HCl,  150 mM NaCl, 10 % glycerol, 10 mM 
glutathione, 1 mM DTT supplemented with 0.5 mM 
PMSF and 1 µg/ml of each bestatin, leupeptin and 
pepstatin). Eluted RECQL4 Protein was dialysed 
overnight against buffer C (pH 8.0, 40 mM Tris-
HCl, 150 mM NaCl, 1 mM DTT, 1  mM EDTA, 40 
% glycerol and protease inhibitors) and stored at -
80° C. 
 
GST pull-down assays  
293T whole cell extracts, containing  over-
expressed full-length RECQL4 or p300 (500 μg of 
total protein), were incubated with 10 μg of purified 
GST- p300 or RecQL4 protein fragments (or GST 
alone), 50 μl glutathione-Sepharose 4B beads (GE 
Healthcare), and 100 μg/ml ethidium bromide in 
buffer B in a total reaction volume of 600 μl. 
Bound proteins were eluted with 30 μl Laemmli 
buffer, boiled for 5 min at 100°C and subjected to 
western blot analysis using α-RECQL4 (Rabbit 
polyclonal, ab34800-100, Abcam) or p300 antibody 
(Mouse polyclonal, ab3164-500, Abcam). 
 
 
Cellculture and indirect immunofluorescence 
assays 
U2OS, 293T and HeLa cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (Gibco) 
supplemented with 10% bovine fetal serum and 1% 
penicillin-streptomycin in 5% CO2  atmosphere at 
37°C. At 50% confluency, cells grown on glass 
slides were transiently transfected with 2 µg of 
appropriate plasmid DNA using Metafectene 
(Biontex). 
For the indirect immunofluorescence assays, cells 
growing on glass slides were incubated in PBS for 
5 minutes, fixed with methanol (30 min at -20°C), 
and washed in acetone (30 sec at -20°C). After a 
blocking step (5% BSA in PBS, 20 min at RT), 
slides were incubated with a mixture appropriate 
antibodies (α-His, 1:200, Goat polyclonal, sc-499-
6, Santa Cruz; α-FLAG, 1:2000, Mouse polyclonal, 
F-1804, Sigma; α-β-Galactosidase, 1:5000, Rabbit 
 polyclonal, ab616, Abcam). Rabbit antibodies were 
detected with AlexaFluor 488 conjugated goat anti-
rabbit IgG (1:400 in blocking buffer, Molecular 
Probes), the goat antibodies were detected with 
AlexaFluor 546 conjugated donkey anti-goat IgG 
(1:400 in blocking buffer, Molecular Probes), and 
mouse antibodies were detected with AlexaFluor 
488 conjugated donkey anti-mouse IgG (1:400 in 
blocking buffer, Molecular Probes). To visualize 
nuclear DNA, slides were incubated with DAPI 
(0.4 µg/ml). After washing, slides were mounted in 
Vectashield (Vector Laboratories) and viewed 
under a ZEISS Axiovert 200M Microscope. Images 
were processed by Axiovision software. For 
statistical analysis at least 200 cells were counted in 
two independent experiments. 
 
Synchronization of cells and DNA damaging 
treatments 
293T cells were grown as described above. For 
G1/S and S phase synchronization, cells (50% 
confluency) were grown for 15h in the presence of 
2 mM thymidine. After washing with PBS, cells 
were grown for 12h in complete medium. 
Subsequent addition of 2 mM thymidine for another 
15h led to synchronization of the cell population in 
G1/S transition. For synchronization in S-phase, the 
cells were released from double-thymidine block by 
washing with PBS and incubated for 4h in complete 
medium before harvesting. For G2/M 
synchronization, cells were grown in the presence 
of nocodazole (400 ng/ml) overnight (12h) before 
harvesting. To induce DNA damage, cells were 
treated with 10 µM Cisplatin (12h), 10 µM 
Etoposide (12h) or 5 µM Bleomycin (12h) before 
harvesting. 
 
Co-immunoprecipitation experiments 
Whole cell extract, supplemented with ethidium 
bromide (100 μg/ml), containing ectopically 
expressed His-RECQL4 (1 mg of total protein) or 
FLAG-p300 (1.5 mg of total protein) respectively, 
was incubated with 1.5μg of anti-p300 antibody 
(mouse polyclonal, 554215, BD Pharmingen) or 
1.5μg of an anti-RECQL4 antibody (Rabbit 
polyclonal, ab 34800-100, Abcam), respectively. 
Immune complexes were bond to protein G-
Sepharose Fast Flow beads (GE Healthcare) for 4h 
at 4°C. The final volume was raised to 1ml with IP 
buffer [20 mM HEPES pH 7.5, 5 mM MgCl2, 80 or 
120 or 160 mM NaCl, 0.1% (w/v) NP40, 
supplemented with 1μg/ml bestatin, leupeptin, and 
pepstatin]. Immunoprecipitated p300 or RECQL4 
protein was visualized by western blot analysis 
using an anti-p300 or anti-RECQL4 antibody, 
respectively, and co-immunoprecipitated His-
RECQL4 or FLAG-p300 protein was visualized by 
western blot analysis using an α-His (Goat 
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 polyclonal, sc-499-6, Santa Cruz) or α-FLAG 
(Mouse, polyclonal, F-1804, Sigma) antibody, 
respectively. 
 
ELISA-based protein binding 
Purified recombinant p300 was diluted to a 
concentration of 20 nM in carbonate buffer [16 mM 
Na2CO3, 34 mM NaHCO3 (pH 9.6)] and added to 
wells of a 96-well microtiter plate (50μl/well). 
Plates were incubated overnight at 4°C. For control 
reactions, wells were pre-coated with an equivalent 
amount of bovine serum albumin (BSA). After 
aspiration of the samples, the wells were blocked 
with blocking buffer [phosphate-buffered saline, 
0.5% (v/v) Tween 20, and 3% (w/v) BSA] for 2 
hours at 37°C (200 μl/well). Following blockage, 
the wells were incubated with increasing 
concentrations of purified recombinant RECQL4 
protein for 1 hour at 37°C. Wells were washed four 
times with blocking buffer to eliminate unbound 
proteins, and incubated with RECQL4 antibody 
(Rabbit polyclonal, 1:2000, ab34800-100, Abcam) 
diluted in blocking buffer. Plates were incubated 
for 1 hour at 37°C. After four washings with 
blocking buffer, horseradish peroxidase-conjugated 
anti-rabbit secondary antibody (1:10,000 in 
blocking buffer) was added and the plates were 
incubated at 37°C for 30 minutes. After extensive 
washing with blocking buffer, the protein 
complexes were detected using o-
Phenylenediamine dichloride (Sigma) dissolved in 
0.1 M citratephosphate buffer (pH 5.0) containing 
0.03% hydrogen peroxide (1 mg/ml). The reactions 
were terminated after 10 minutes by adding 50 μl of 
2 M H2SO4. The plates were scanned in a 
microplate reader (Molecular Devices) for 
absorbance at 450 nm. The A450 values, corrected 
for background signal in the presence of BSA, were 
plotted as a function of the concentration of 
RECQL4 protein using the GraphPad Prism 
software. 
 
In vivo Acetylation Assay  
One milligram of total protein extracted from 293T 
cells, ectopically expressing RECQL4 and one of 
the selected histone acetyltransferases (p300, 
GCN5, pCAF, HAT1), was incubated for 4h at 4°C 
with 2 µg of an anti-His antibody (Goat polyclonal, 
sc-499-6, Santa Cruz) bound to protein A-
Sepharose 4B beads (GE Healthcare). 
Immunoprecipitated RECQL4 protein was 
visualized by western blot analysis using the anti-
His antibody. The membrane was stripped in 50 
mM Tris pH8, 5 mM β-mercaptoethanol, 2% 
sodium dodecyl sulfate for 1h at 52°C and 
acetylated lysine residues were visualized by a 
polyclonal anti-acetylated lysine antibody (Rabbit 
polyclonal, 1: 1000, 9441-5, Cell Signaling). 
 
 
 
In vitro Acetylation Assay  
Purified GST-RECQL4 fragments (1  g) were 
incubated with 0.1 µCi [14C] acetyl coenzyme A 
(CFA390, Amersham Biosciences) and purified 
p300 (1  g) in 30 µl HAT-Buffer (50 mM Tris [pH 
8.0], 10% [v/v] glycerol, 150 mM NaCl, 1 mM 
DTT, 1 mM PMSF, 10 mM Na butyrate) at 30°C 
for 1h. The reactions were subjected to SDS-PAGE 
analysis. Gels were stained with Coomassie and 
subsequently subjected to autoradiography. 
 
ATPase Assay  
Purified full length RECQL4 (40 nM) was 
incubated in the presence or absence of p300 in 10 
µl HAT Buffer (50 mM Tris pH 7.5, 50 mM KCl, 
10% Glycerol, 1 mM DTT, 1 mM PMSF, 1 mM 
Na-Butyrate) at 30°C for 30 min. Where required 
Ac-Co-A was added to a final concentration of 50 
µM. This mixture was then supplemented with M13 
ssDNA plasmid (75μM Nucleotides) and 10 µl of 
buffer A (30 mM Tris–HCl, pH 7.5, 2.5 mM 
MgCl2, 1 mM DTT, and 100 µg/ml BSA) 
containing 1 mM [_-32P]ATP. The reactions were 
incubated at 37°C for 30 min and the released 32Pi 
was separated from the unhydrolyzed ATP by thin 
layer chromatography using PEI-Cellulose 
(Marchery-Nagel). The data was quantified using 
the scion image software. 
 
Immunodepletion 
Two micrograms of rabbit polyclonal anti-RECQL4 
antibody (ab34800-100, Abcam) or control rabbit 
IgG (sc-2027, Santa Cruz) were incubated for 1 h at 
4°C with 40 μl Protein G Sepharose beads (GE 
Healthcare). After washing three times with 
reaction buffer, antibody-bound beads were 
incubated with 100 nM RECQL4 in the reaction 
buffer for 1 h at 4°C. Beads were removed by 
centrifugation. Supernatants were assayed for 
ATPase activity as described above.  
 
 
RESULTS 
 
In vivo acetylation of RECQL4 by p300 and 
interaction of the full length proteins 
We wanted to investigate whether RECQL4 is 
acetylated in mammalian cells. To identify a 
potential acetyltransferase that acetylates RECQL4 
in vivo, His-RECQL4 was overexpressed in 293T 
cells with each of the four major human 
acetyltransferases (p300, pCAF, Gcn5, and HAT1). 
Notably, we were forced to use overexpressed 
RECQL4 protein in this assay due to a low 
expression level of the endogenous RECQL4 gene. 
An anti-His antibody was used to 
immunoprecipitate RECQL4 from whole cell 
extracts (Fig. 1A, upper left panel). A control IgG 
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 antibody failed to precipitate RECQL4 and 
confirmed the specificity of the anti-His antibody 
for His-RECQL4 (Fig. 1A, lane 6). Acetylation 
status of His-RECQL4 was visualized by western 
blot analysis using an antibody recognizing 
acetylated lysines (Fig. 1A, lower left panel). 
Although western blot analysis revealed that all 
four acetyltransferases (p300, pCAF, GCN5, or 
HAT1) were expressed to similar levels (Fig. 1A, 
right panel), RECQL4 was found to be strongly 
acetylated only in cells overproducing p300, 
suggesting that p300 may be the acetylatransferase 
that acetylates RECQL4 in vivo. Additionally, 
neither synchronizing cells in different stages of the 
cell cycle (G1/S and S-phase using double 
thymidine block, G2/M using nocodazole) nor 
treatment with different DNA damaging agents 
(Cisplatin, Etoposide, Bleomycin) triggered 
RECQL4 acetylation in vivo (Supplementary Figure 
1A/B).  
We next analysed whether RECQL4 and p300 
interact in human cells. For this, FLAG-p300 was 
transiently transfected into 293T cells and total cell 
extract was immunoprecipitated with anti-RECQL4 
antibody and analysed by immunoblotting using an 
anti-FLAG antibody. We found that FLAG-p300 
was efficiently co-precipitated by the anti-RECQL4 
antibody (Fig. 1B, lane 3), but was not detected 
when the control IgG antibody was used (Fig.1B, 
lane 2). To further confirm the interaction between 
RECQL4 and p300 in human cells, the reciprocal 
coimmunoprecipitation experiment was also carried 
out using a polyclonal anti-p300 antibody. The His-
RECQL4 could be specifically co-
immunoprecipitated with endogenous anti-p300 
antibody (Fig. 1B, lane 6), but not with the control 
IgG antibody (Fig. 1B, lane 5). It should be noted 
that cell extracts used in the above-mentioned 
experiments were supplemented with ethidium 
bromide excluding the possibilitiy that association 
of RECQL4 and p300 is mediated by DNA.  
We next performed an ELISA-based protein-
binding assay using purified recombinant proteins 
to determine whether RECQL4 and p300 interact 
directly. Increasing concentrations of purified 
recombinant RECQL4 ranging from 0 to 40 nM 
were incubated in wells that had been pre-coated 
with purified p300 at a concentration of 20 nM and 
subsequently blocked with BSA to prevent non-
specific interactions. After extensive washing, the 
bound RECQL4 was incubated with a specific anti-
RECQL4 polyclonal antibody followed by a 
colorimetric assay to quantify the binding. In 
control experiments, RECQL4 was incubated in 
wells pre-coated only with BSA. We found that 
RECQL4 specifically bound to p300-coated wells 
in a dose dependent manner, but was not in wells 
pre-coated with BSA, indicating a direct interaction 
 in the nanomolar range (Fig. 1C). Taken together, 
these data indicate that p300 acetylates RECQL4 in 
vivo, that RECQL4 and p300 form a complex in 
human cells, and that the proteins interact directly 
in vitro.  
 
Mapping of the RECQL4 and p300 interaction 
regions 
To confirm the RECQL4/p300 interaction and to 
map the RECQL4 interaction region in p300, 
RECQL4 was divided into four fragments which 
were subsequently cloned and expressed as 
glutathione S-transferase (GST) fusion proteins 
(Fig. 2A and 2B). GST pull-down experiments with 
these fragments were performed using total cell 
extracts containing overexpressed FLAG-p300 
derived from transiently transfected 293T cells. 
Western blot analysis of bound proteins using an 
anti-FLAG antibody indicated that only fragment 2 
of RECQL4 was able to interact with full length 
p300 (Fig. 2C, lane 4). This fragment spans amino 
acid (aa) residues 1-408 of RECQL4 and contains 
the RECQL4 nucleolar localization signal (NOS) 
previously mapped to aa 376-386 (26) and a part of 
the helicase domain (see also Fig. 2A).  
To map the RECQL4-interaction region in p300, 
p300 was also divided into several fragments 
labelled 1-5, which were subsequently expressed 
and purified as GST fusions (Fig. 2D and 2E). GST 
pull-down experiments were performed using 
whole cell extracts of 293T cells over-producing 
His-RECQL4. Western blot analysis of bound 
proteins using a specific anti-His antibody indicated 
that only fragment 4 of p300 was able to interact 
with full length RECQL4 (Figure 2F, lane6). This 
fragment spans aa 1459-1892 and contains a part of 
the p300 HAT domain that was previously shown 
to interact with human FEN-1 (37).  
 
p300 enhances RECQL4 ATPase activity 
The physical interaction between RECQL4 and 
p300 suggested the possibility that the two proteins 
might affect each other’s activities. To test this 
hypothesis, we first wanted to determine whether 
purified p300 influences RECQL4 ATPase activity.  
In order to purify full length RECQL4 from E.coli, 
we constructed an expression vector in which the 
RECQL4 cDNA was flanked by an N-terminal 
GST and a C-terminal His tag (Fig. 3A). After large 
scale expression of RECQL4 in E.coli, we affinity 
purified the protein using glutathione-Sepharose 
and Nickel-NTA Agarose and analysed the peak 
fraction by Coomassie staining (Fig. 3B, left panel) 
and by western blot using anti-GST and anti-
RECQL4 antibodies (Fig. 3B, right panel). In 
agreement with previously published data, the yield 
of RECQL4 protein was very low, which is 
presumably due to proteolysis in E. coli (44)  
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Furthermore, we tested whether our RECQL4 prep 
possessed single-strand DNA (ssDNA) and Mg+2 
dependent ATPase activity as previously described 
(44). As shown in Fig. 3C, the hydrolysis of ATP 
by RECQL4 was indeed dependent on ssDNA and 
Mg+2. Only minor levels of ATPase activity were 
observed with Ca+2 as a co-factor, as well as if 
ssDNA was substituted with dsDNA or omitted. 
Additionally, we immunodepleted RECQL4 from 
the purified peak fraction using an anti-RECQL4 
antibody and assayed the supernatant for ATPase 
activity (Fig. 3D). A twofold reduction in ATPase 
activity was observed compared to untreated 
sample or sample immunodepleted using a control 
rabbit IgG. This further confirms that the ATPase 
activity in the peak fraction is mediated by  
RECQL4 protein.  
To investigate whether p300 affects the RECQL4 
ATPase activity, RECQL4 was incubated with 
recombinant p300 purified from insect cells and 
subsequently tested in ATPase assay (Fig. 3E and 
3F). Interestingly, the ATPase activity of RECQL4 
preincubated with p300 was increased twofold 
compared to RECQL4 alone or RECQL4 
preincubated with another human acetyltransferase 
Gcn5 (Fig. 3E). p300 alone showed no ATPase 
activity, confirming that purified p300 from insect 
cells was not contaminated with an ATPase 
activity.  
We next wanted to investigate whether acetylation 
of RECQL4 would have an effect on its ATPase 
activity. Purified RECQL4 was preincubated with 
purified p300 either in the presence or absence of 
Acetyl Co-enzyme A (AcCoA) and subsequently 
tested in ATPase assay (Fig. 3F). Again, p300 had a 
stimulatory effect on RECQL4 ATPase activity but 
acetylation of RECQL4 by p300 
(RECQL4+p300+AcCoA) slightly decreased this 
stimulatory effect. We found that ATPase activity 
of RECQL4 in the presence of AcCoA was only 
slightly lower than that measured in its absence, 
indicating that p300-mediated acetylation of 
RECQL4 has no significant effect on its ATPase 
activity. 
 
Identification of acetylation sites on RECQL4 in 
vitro and in vivo 
Several studies revealed that p300 preferentially 
acetylates stretches of lysine residues of substrate 
proteins (37, 45-48). The RECQL4 amino acid 
sequence contains 32 lysine residues and the only 
lysine stretch is located in the previously identified 
nucleolar localization signal (NOS) of RECQL4 
with five lysine residues at positions 376, 380, 382, 
385, and 386 (26). Two His-RECQL4 NOS 
mutants, with all five lysine residues mutated to 
either alanine (K A) or to arginine (K R), were 
 generated using site-directed mutagenesis in order 
to identify the extent of acetylation of  the NOS 
lysine residues within RECQL4 (Fig. 4A). 
Wildtype (WT), K A, and K R His-RECQL4 
were subsequently co-transfected into 293T cells in 
the presence or absence of p300, and 
immunoprecipitated from whole cell extracts using 
an anti-His antibody (Figure 4B, upper left panel). 
A control IgG serum confirmed the specificity of 
the anti-His antibody for His-RECQL4 in the 
immunoprecipitation reaction (Fig. 4B, lane 7). The 
extent of RECQL4 acetylation was visualized by 
western blot analysis using an anti-acetylated lysine 
antibody (Fig. 4B, lower left panel). Although co-
transfection of WT His-RECQL4 and p300 resulted 
in acetylation of RECQL4 (Fig. 4B, lane 6), the 
acetylation of the K A (Fig. 4B, lane 2) and K R 
(Fig. 4B, lane 4) His-RECQL4 mutants was not 
detected, suggesting that at least one of the lysine 
residues at positions 376, 380, 382, 385, and 386 of 
RECQL4 is required for acetylation by p300. To 
further investigate which of the five lysine residues 
is acetylated in vivo, we generated single (K382R) 
(Fig. 4B, lanes 9 and 10), double (K385,386R) (Fig. 
4B, lanes 11 and 12) and triple (K376,380,382R) 
(Fig. 4B, lanes 13 and 14) mutants by site directed 
mutagenesis. The three mutants were co-transfected 
in the presence or absence of p300 in 293T cells 
and analysed as described above (Fig. 4B, left 
panel). Co-transfection of all three mutants and 
p300 resulted in acetylation of RECQL4 (Fig. 4B, 
lanes 10, 12 and 14), suggesting that more than one 
lysine residue at the aa positions 376, 380, 382, 
385, and 386 is acetylated by p300. 
To confirm that the stretch of lysine residues in 
RECQL4 at the positions 376, 380, 382, 385, and 
386 is acetylated by p300, RECQL4 was divided 
into several fragments, labelled A-E, that were 
subsequently expressed and purified as GST fusion 
proteins (Fig. 4C). Subsequently, p300 purified 
from SF9 insect cells was incubated with the above 
mentioned GST-RECQL4 fragments and [14C] 
acetyl coenzyme A. The reactions were analysed by 
SDS PAGE. After Coomassie-staining (Fig. 4D, 
left panel), the gel was subjected to 
autoradiography and revealed that p300 was self-
acetylated (28, 29) and was able to acetylate the 
fragment B of RECQL4 (Figure 4B, right panel9). 
This fragment spans amino acid residues 359-478 
including the putative NOS (aa 376-386) of 
RECQL4. Furthermore, this fragment also contains 
a large part of the p300 interaction region (aa 1-
408) that was mapped in the experiment shown in 
Fig. 4B. Importantly, there was no detectable 
acetylation of RECQL4 fragment C, which covers 
the same region as fragment B but has all five 
lysine residues mutated to alanines. The difference 
in electrophoretic mobilities of fragments B and C 
can be explained by the lack of positive charge in 
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 the alanine mutant. It should be noted that 
Coomassie blue staining of the gel confirmed that 
comparable amounts of RECQL4 fragments were 
used in each acetylation reaction. 
In order to further investigate which of the 
fiveRECQL4 lysine residues are acetylated by 
p300, purified 6xHisRECQL4aa359-478 from 
E.coli was acetylated in vitro by p300 in the 
presence of cold acetyl coemzyme A and analysed 
by SDS-PAGE. Subsequent in gel digestion and 
LC-MSMS analyses of the acetylated fragment 
6xHisRECQL4aa359-478 using Lys-C, 
chymotrypsin and pepsin respectively, did not 
allow us to detect peptides covering the majority of 
the sequence. This could be either due to 
difficulties with the cleavage of this highly charged 
sequence or problems with the chromatography in 
the HPLC or the detection of the peptides in the 
MS. We could only detect one acetylated peptide in 
the Lys-C digest with the sequence 
K386GECFGGGGATVTTK400 and acetylation on 
lysine residue 386.  
 Thus, we conclude from the in vivo and in 
vitro acetylation assays that p300 acetylates 
RECQL4 on one or more of the lysine residues at 
positions 376, 380, 382, 385, and 386 of RECQL4 
previously characterized NOS/NLS of the RECQL4 
aa sequence. 
 
Role of lysine residues 376, 380, 382, 385, 386 in 
RECQL4 localization in mammalian cells 
We next investigated the functional significance of 
K376, K380, K382, K385, and K386 acetylation by 
analyzing the subcellular distribution of RECQL4 
protein in human cells. To that end, we transiently 
overexpressed full length His-RECQL4 in HeLa 
cells and examined its subcellular localization by 
indirect immunofluorescence using an α-His 
antibody (Fig 5A, top panels). We found that in 
70% of the cells, RECQL4 was localized 
predominantly in the nucleus. In 22% of the cells, 
RECQL4 was equally distributed between nucleus 
and cytoplasm, while predominant cytoplasmic 
localization of RECQL4 protein was observed in 
8% of the cells (Fig. 5B, bars on the left).  Our 
observation is consistent with previously published 
biochemical and immunofluorescence data with 
overexpressed and endogenous RECQL4, showing 
that RECQL4 is found both in the nucleus and the 
cytoplasm of different cell lines examined (23, 25, 
27). Therefore, we considered His-RECQL4 to be 
an adequate tool to further characterize the cellular 
localization of RECQL4. We next tested the two 
K A  and K R  His-RECQL4 mutants for the 
localization in HeLa cells, since the RECQL4 N-
terminal basic motif spanning aa 376-386 
(KQAWKQKWRKK) was previously reported to 
have nucleolar localization activity (26). Each of 
 the mutants were transiently transfected in HeLa 
cells and the expressed proteins were detected by 
indirect immunofluorescence using an α-His 
antibody (Fig.5A, middle/lower panels). No 
significant difference in subcellular localization 
between the RECQL4 wild type and RECQL4 K  
R mutant was observed (Fig.5A/4B, middle panels/ 
bars in the middle).  Interestingly, though, the 
RECQL4 K A mutant was mostly localized to the 
cytoplasm of HeLa cells. Similar results were 
obtained using U2OS cells and cell type specific 
observations could therefore be excluded 
(Supplementary Figure 2). Importantly, our 
findings are contradictory to the observations by 
Woo et al. (26), who found nucleolar exclusion (but 
nucleoplasmic localization) of GFP-RECQL4 
lacking the basic motif. To further verify the 
validity of our results, we cloned the nucleotides 
encoding the basic motif (aa 376-386) of RECQL4 
(NLS β-Gal) or the K   A mutant sequence (NLS 
K   A β-Gal) N-terminally to the E.coli β-
Galactosidase cDNA (Fig. 5C).  Transiently 
overexpressed E.coli β-Galactosidase was found to 
be localized almost entirely to the cytoplasm in 
Hela cells (Fig. 5D, top, Fig. 5E, left). Intriguingly, 
the RECQL4 wild type basic motif fused to the β-
Galactosidase protein was able to import this 
100kDa protein to the nucleus (Fig. 5D/5E, 
middle), while the K   A β-Gal fusion protein 
failed to be imported and was localized mostly to 
the cytoplasm (Fig. 5D, low, Fig. 5E, right). The 
same experiment was repeated by using 293T cells 
(Supplementary Figure 3). Thus, we conclude from 
this experiment that positively charged side chains 
of Lys 376, 380, 382, 385, and 386 within the N-
terminal basic motif (KQAWKQKWRKK) are 
essential for the nuclear localization of RECQL4. 
 
A portion of RECQL4 translocates to the 
cytoplasm upon acetylation by p300 
We next wanted to examine the cellular localization 
of RECQL4 protein in human cells that express 
either the wild-type or mutated p300. To that end, 
we first transiently expressed in HeLa cells FLAG-
p300 and FLAG-p300ΔHAT, a catalytic dead 
mutant lacking part of the HAT domain, and 
visualized both proteins by indirect 
immunofluorescence using an α-FLAG antibody. 
As expected, both proteins were localized entirely 
to the nucleus of HeLa cells (Fig. 6A). We then 
investigated the functional consequence of the 
RECQL4 acetylation in vivo. Immunofluorescence 
experiments on co-transfected HeLa cells (His-
RECQL4/ FLAG-p300 and His-RECQL4/FLAG-
p300ΔHAT, respectively) showed that the catalytic 
activity of p300 enhances about three-fold the 
number of cells in which RECQL4 is mainly 
cytoplasmic (Fig. 6B/ 6C). In accordance with this 
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 observation, p300 catalytic activity didn’t drive the 
accumulation of RECQL4 K R mutant in the 
cytoplasm, confirming that these lysine residues are 
responsible for p300-induced RECQL4 
relocalization (Fig. 6D/ 6E).  
To further confirm that the observed cytoplasmic 
translocation of RECQL4 is indeed due to the 
acetylation, HeLa cells were transfected with His-
RECQL4 or His-RECQL4 K R mutant and 
incubated for 30h in the presence of the histone 
deacetylase inhibitors Trichostatin A (TSA) and 
nicotinamide (NA). As shown in Fig. 6F and 6G, 
TSA and NA induced a translocation of His-
RECQL4 to the cytoplasm, while the localization of 
the His-RECQL4 K R Mutant was not affected. 
These findings indicate that protein acetylation, 
enhanced by TSA and NA, positively regulates the 
translocation of RECQL4 from the nucleus to the 
cytoplasm. Similar results were obtained when 
U2OS cells were used instead of HeLa cells (data 
not shown). 
Collectively, these data imply that the subcellular 
localization of RECQL4 is regulated at least in part 
by acetylation and that p300 acetyltransferase 
activity on the lysine residues within the RECQL4 
basic motif (KQAWKQKWRKK) is crucial for its 
translocation to the cytoplasm. 
 
 
DISCUSSION 
 
Proper RECQL4 activity is required for the 
maintenance of genome stability as reflected by the 
fact that three different human disorders 
characterized by cancer suceptibility and premature 
aging have been associated with mutations in the 
RECQL4 gene: Rothmund-Thomson (RTS), 
RAPADILINO, and Baller-Gerold (BGS) 
syndromes (10). Although RTS, RAPADILINO 
and BGS syndromes caused by mutations in 
RECQL4 are rare (i.e. they currently affect 
approximately 400 individuals in total), from a 
molecular biology aspect it is important to 
investigate how faulty RECQL4 hinders the normal 
processes of DNA repair and replication, and how 
defects in these processes lead to such a broad 
spectrum of clinical features, as observed in RTS, 
RAPADILINO and BGS patients.  
Investigation of RECQL4 subcellular localization 
was an object of extensive studies in the last couple 
of years (9, 23, 25-27). Different data suggested 
that RECQL4 is located in the nucleus and the 
cytoplasm of different cell lines examined, but the 
molecular mechanism by which RECQL4 is 
translocated to the cytoplasm and the cytoplasmic 
function of RECQL4 remains to be elucidated. This 
study provides the first evidence of a physical and 
functional interaction between RECQL4 and the 
 transcriptional coactivator and histone 
acetyltransferase p300. This interaction was 
confirmed with purified recombinant RECQL4 and 
p300 proteins indicating that the interaction is 
direct. The N-terminal amino acids 1-408 of 
RECQL4 and the amino acid residues 1459–1892 
of p300 were necessary and sufficient for the 
interaction of RECQL4 with p300. Investigations of 
the biochemical consequences of RECQL4/p300 
interaction revealed that p300 specifically 
stimulates the RECQL4 ATPase activity in vitro, 
while acetylation of RECQL4 decreases this effect. 
Our findings constitute two important and novel 
discoveries. First, we show in vitro and in vivo that 
p300 specifically triggers RECQL4 protein 
acetylation on several lysine residues of the 
conserved N-terminal basic motif spanning amino 
acids 376-386 (KQAWKQKWRKK), and that this 
acetylation positively regulates the translocation of 
a subset of RECQL4 from the nucleus to the 
cytoplasm. Since p300 catalytic activity didn’t 
drive the accumulation of RECQL4 K R mutant in 
the cytoplasm, our data indicate that Lys 376, 380, 
382, 385, 386 of RECQL4 positively regulate the 
translocation of RECQL4 from the nucleus to the 
cytoplasm in two different human cell lines. In 
addition, the exposure of these cell lines to histone 
deacetylase inhibitors Trichostatin A (TSA) and 
nicotinamide (NA), both of which increase the level 
of protein acetylation, induced the cytoplasmic 
translocation of the wild-type RECQL4 but not 
RECQL4 K R mutant further confirming the 
importance of Lys residues 376, 380, 382, 385, 386 
of RECQL4 in the cytoplasmic translocation of 
RECQL4. 
Secondly, we show that Lys 376, 380, 382, 385, 
386 of RECQL4 within the N-terminal basic motif 
(KQAWKQKWRKK) are essential for the nuclear 
localization of RECQL4. The contradictory 
observations by Woo et al. (26), who found 
nucleolar exclusion (but nucleoplasmic 
localization) of GFP-RECQL4 lacking the basic 
motif could be explained by the fact that deleting 
10 amino acids from the original RECQL4 
sequence may influence its proper native folding 
and localization. In accordance to our data, Burks et 
al. demonstrated that RECQL4 aa 363-492 are 
crucial for nuclear import and localization of GFP-
RECQL4 and a conserved block of 22 amino acids 
(aa 365-386) was able to import GFP to the nucleus 
of mammalian cells (25). These authors also 
showed that a conserved motif (VLPLV) within 
RECQL4 aa 420-463 (encoded by exon 7) may 
play a role in nuclear retention of the RECQL4 
protein.  
Furthermore, we have provided evidence that the 
acetylation of RECQL4 does not significantly 
change during the cell cycle or upon cellular 
treatment with different DNA damaging agents 
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 including cisplatin, etoposide, and bleomycin. 
Interestingly, these data differ from those obtained 
for WRN helicase which showed that DNA damage 
by either UV light or ionizing radiation induces 
p300-dependent WRN translocation from nucleolus 
to the nucleocytoplasmic foci (49). Thus, further 
studies are needed to understand on the molecular 
level which endogenous and exogenous factors are 
required to trigger p300-dependent acetylation of 
RECQL4.  
How might p300 regulate subcellular localization 
of RECQL4? One possible scenario, as previously 
shown for transcription factors HMGB1 (50) and 
E1A (51), could be that p300-mediated acetylation 
negatively affects the function of the RECQL4 NLS 
(aa 376-386) and thus disrupts its association with 
the nuclear import machinery, which leads to 
subsequent cytoplasmic accumulation of RECQL4 
protein. Supporting this hypothesis, it has been 
recently demonstrated that RECQL4 is found in 
complex with UBR1/UBR2 at least partially in 
cytosolic extracts of HeLa cells (27). UBR1/UBR2 
belong to the family of E3 ubiquitin ligases of the 
N-end rule pathway, which is part of the ubiquitin 
proteasome system (52). It is therefore tempting to 
speculate that, after a portion of RECQL4 is 
acetylated by p300 in the nucleus, RECQL4 is 
translocated to the cytoplasm where the interaction 
with UBR1/UBR2 takes place and leads to a 
subsequent degradation by the proteasome of the N-
end rule pathway. Finally, we note that we can not 
at the present time rule out the possibility that 
RECQL4 has some other role in the cytosol that 
still awaits further investigations.  
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Figure Legend 
 
FIG.1 p300 acetylates RECQL4 in vivo and the two proteins form a stable complex.  
(A) Left panel: His-RECQL4 was ectopically expressed in 293T cells along with with FLAG-p300, myc-
pCAF, HA-Gcn5 or FLAG-HAT1 histone acetyltransferases (HATs). His-RECQL4 was then 
immunoprecipitated with an α-His antibody (IP: 6xHis-RECQL4) and analyzed by Western blot (upper 
panel). The same nitrocellulose membrane was stripped and re-probed with an α-acetyl-lys (α-Ac-lys) 
antibody (lower panel). Right panel: Western blot analysis of overexpressed HATs (FLAG-p300, myc-PCAF, 
HA-Gcn5, and FLAG-HAT1/ FLAG-p46 heterodimer). 50 μg of  total protein extract were loaded in each 
lane. As negative controls (-) the same amount of extracts of untransfected 293T cells was analyzed. (B) 
RECQL4 and p300 form a complex in human cells.  Left panel: 293T cells were transiently transfected with 
FLAG-p300 expression vector. Total cell extract derived from these cells was immunoprecipitated with an α-
RECQL4 antibody or control IgG, and was analyzed by SDS PAGE. One-tenth (100 μg) of the same total cell 
extract was used as input control (lane 1).  Immunoprecipitated FLAG-p300 and RECQL4 were detected by 
Western blotting using an α-FLAG and α-RECQL4 antibody, respectively (lane 3). Reciprocal co-
immunoprecipitation is shown in the right panel: lane 4, input; lane 5, immunoprecipitation with the control 
IgG; lane 6, immunoprecipitation with an α-p300 antibody using total cell extracts derived from 293T cells 
overexpressing His-RECQL4. (C) Binding of RECQL4 to p300 as a function of RECQL4 concentration. 
Increasing concentrations of RECQL4 (0 - 40 nM) were incubated at 37°C for 1 hour in wells of an ELISA 
plate that were pre-coated with the p300 protein (20nM) and subsequently blocked with 3% BSA. After 
extensive washing, bound RECQL4 protein was detected as described in Materials and Methods. Absorbance 
values measured were corrected by subtracting background values obtained with BSA-coated wells. 
 
FIG.2 Mapping of interaction domains between p300 and RECQL4. 
(A) Schematic representation of RECQL4 and its deletion variants used in this study. (B) SDS-PAGE 
analysis of bacterially expressed and purified GST-RECQL4 fragments 1-4. Gel was stained with Coomassie 
blue. (C) GST pull-down assay showing binding of FLAG-p300 to bacterially expressed GST RECQL4 
fragments 1-4. GST-RECQL4 fragments bound to Glutathione-Sepharose beads were incubated with whole 
cell extract (1 mg of total protein) derived from 293T cells overexpressing p300. p300 binding was analyzed 
by western blotting using anti FLAG antibody. 
 (D) Schematic representation of p300 and its deletion variants. (E) SDS-PAGE analysis of bacterially 
expressed and purified GST-p300 fragments 1-5. (F) GST pull-down assay showing binding of His-RECQL4 
to bacterially expressed GST-p300 fragments 1-5. GST-p300 fragments bound to Glutathione-Sepharose 
beads were incubated with whole cell extract (1 mg of total protein) derived 293T cells over-expressing 
RECQL4. RECQL4 binding was analyzed by western blotting using anti-His antibody.  
 
FIG.3 p300 has a stimulatory effect on the RECQL4 ATPase activity. 
(A) Schematic representation of the RECQL4 construct used for the purification of the full length protein. 
RECQL4 protein was expressed in E.coli as a double-tagged fusion protein (GST-RECQL4-His). (B) After 
purification of GST-RECQL4-His using Glutathione-Sepharose and Nickel-NTA agarose, the eluted protein 
was analyzed by SDS-PAGE followed by Coomassie staining (left panel) and immunoblotting using α-GST- 
and α-RECQL4 antibodies (right panel). The arrows indicate the full length GST-RECQL4-His protein. (C) 
ssDNA and Mg+2  are crucial co-factors for RECQL4 ATPase activity. Reactions containing 40 nM RECQL4, 
1mM [γ -32P] ATP, 50mM KCl, and either 2.5mM Mg+2 or Ca+2, and either M13 ssDNA or ds plasmid DNA  
(75μM nucleotides) were incubated at 37°C for 30 minutes. The relative amount of hydrolysed ATP was 
determined using thin layer chromatography and Scion Image software. (D) RECQL4 immunodepletion 
inhibits ATPase activity. Rabbit polyclonal α-RECQL4 antibody or control rabbit IgG immobilized to protein 
G Sepharose were used to immunodeplete RECQL4 as described in Material and Methods. Increasing 
amounts of each sample (white box, RECQL4 antibody; grey box, control antibody) were subsequently 
assayed for ATPase activity and compared with the activity of untreated RECQL4 sample (black box). (E) 
p300 stimulates RECQL4 ATPase activity.  Reactions containing 40 nM RECQL4, 1mM [γ -32P] ATP, 50 
mM KCl, 2mM Mg+2 and M13 ssDNA (75μM Nucleotides) were incubated at 37°C for 30 minutes in the 
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presence or absence of purified p300 (100nM) or Gcn5 (40nM). (F) Acetylation of RECQL4 by p300 slightly 
decreases its ATPase activity. RECQL4 and p300 were preincubated together in the presence or absence of 
cold acetyl- Coenzyme A (AcCoA) for 30 min at 30°C and the samples were subsequently assayed for 
ATPase activity. Same ATPase reaction conditions as in (E) have been used. The data points in all graphs (C-
F) represent average values of at least two independent experiments. 
 
FIG.4 Mutation of lysine residues Lys-376, Lys-380, Lys-382, Lys-385 and Lys-386 abrogates the 
acetylation of RECQL4 by p300 in vitro and in vivo. 
(A) Amino acid sequence of RECQL4 nucleolar localization signal (NOS) sequence. Wild-type sequence is 
highlighted in the orange box. Lysine to alanine (K A) mutated NOS sequence (solid outline) and lysine to 
arginine (K R) mutated NOS sequence (dashed outline) were generated by site-directed mutagenesis. 
Mutated residues are underlined. (B) Left panel: Effect of mutation of lysine residues on in vivo acetylation of 
RECQL4. Using anti-α-His antibody, wild-type (WT), K A, and K R nucleolar localization signal mutants 
of His-RECQL4 were immunoprecipitated (IP) from extracts of 293T cells co-transfected with p300 
expression vector  (+) or control vector (-)  (upper panel). Acetylated His-RECQL4 was detected by western 
blot analysis using anti-α-acetylated lysine antibody (lower panel). Right panel: Same as left panel but the 
effect of single (K382R), double (K385, 386R) and triple (K376, 380, 382R) RECQL4 NOS mutations on its 
in vivo acetylation was tested. (C) Schematic representation of RECQL4 and its deletion variants used in this 
study. Italicized numbers indicate terminal amino acid positions. Solid black box, nucleolar localization 
signal (NOS); striped box, NOS with five lysine to alanine point mutations; green box, RecQ DNA helicase 
domain. (D) p300 purified from insect cells was incubated with [14C] acetyl coenzyme A and purified GST-
RECQL4 fragments or purified histone octamers. Left panel shows the Coomassie-stained SDS-PAGE gel, 
while the right panel shows the autoradiogram of the same gel. Asterisks indicate protein bands with 
predicted molecular weight of the corresponding purified GST-RECQL4 fragment. Double dagger indicates 
band with molecular weight corresponding to acetylated RECQL4-B fragment in autoradiogram. 
 
FIG.5 Mutation of RECQL4 lysine residues Lys-376, Lys-380, Lys-382, Lys-385 and Lys-386 to alanine, 
but not to arginine, cause relocaliztion of RECQL4 to the cytoplasm of human cells. 
(A) His-tagged RECQL4 (wt) and the indicated His-RECQL4 K R and K A mutants were expressed in 
HeLa cells and visualized by indirect immunofluorescence using an α-His antibody (middle panels, α-
HisRECQL4, red). The left panels show DAPI-stained nuclei (blue) and the right panels show the merged 
images of α-HisRECQL4 (red) and DAPI (blue) staining. (B) The histograms show the percentages of 
transfected cells that show an equal distribution of RECQL4 between nucleus and cytoplasm (N=C), a 
prevalence of RECQL4 in the cytoplasm (N<C) or a prevalence of RECQL4 in the nucleus (N>C). The 
plotted data indicate the mean ± standard deviation of two independent transfection experiments in which 
more than 200 transfected cells were analyzed each time. (C) Schematic representation of the N-terminal β-
Galactosidase fusion constructs. RECQL4 nucleotides encoding amino acids 376-386 (wt) and the indicated 
K A mutant sequences were N-terminally cloned to the full length cDNA of the E.coli β-Galactosidase gene 
and the fusion proteins were transiently expressed in HeLa cells. (D) β-Galactosidase and the indicated N-
terminal fusion constructs (NLS-β-Gal and NLS-β-Gal K A) were transiently transfected into HeLa cells 
and expressed proteins were visualized by indirect immunofluorescence using an α-β-Galactosidase antibody 
(middle panels, α- β-Gal, red). DAPI-staining is shown in the left panels and right panels show merged 
pictures (Merge). (E)  Quantitative analysis as in (B). 
 
FIG.6 p300 activity-dependent translocation of RECQL4 protein to the cytoplasm. 
(A) p300 and p300 ∆HAT a catalytic dead mutant, localize to the nucleus in mammalian cells. FLAG-tagged 
p300 or FLAG-p300 ∆HAT proteins were transiently expressed in HeLa cells and visualized by indirect 
immunofluorescence using an α-FLAG antibody (middle panels). DAPI-stained nuclei are shown in the left 
panels, while the merged pictures (Merge) are shown by the right panels. (B+D) His-tagged RECQL4 (B) or 
the indicated His-RECQL4 K R Mutant (D) proteins were co-expressed with FLAG-tagged p300 or FLAG-
p300 ∆HAT proteins in HeLa cells. RECQL4 (B) and RECQL4 K R Mutant (D) proteins were visualized 
with an α-His antibody, while p300 and p300 ∆HAT proteins were visualized with an α-FLAG antibody by 
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indirect immunofluorescence (middle panels). DAPI-staining shows nuclear DNA (left panels) and right 
panels show merged pictures (Merge). (C+E) Quantification of (B+D). The histograms show the percentages 
of cells out of transfected cells that show an equal distribution of RECQL4 between nucleus and cytoplasm 
(N=C), a prevalence of RECQL4 in the cytoplasm (N<C) or a prevalence of RECQL4 in the nucleus (N>C). 
(F) Histone deacetylase (HDAC) inhibitors trichostatin A (TSA) and nicotin amide have a slight effect on the 
translocation of RECQL4 to the cytoplasm. 
His-RECQL4 and His-RECQL4 K R mutant were transiently overexpressed in HeLa cells. 24 hours post 
transfection, TSA and nicotin amide were added for an additional 30hours.Cells were subsequently fixed and 
expressed proteins were visualized as mentioned above. (G)  Quantification of (F). (C, E, G) The plotted data 
indicates the mean ± standard deviation of two independent transfection experiments in which more than 200 
transfected cells were analyzed each time. 
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5 Conclusion and Perspective 
 
 
RECQL4 is a member of the conserved RecQ family of helicases. There are five 
human homologues named: RECQL1, BLM, WRN, RECQL4, and RECQL5. 
Mutations in three of the five family members, BLM, WRN and RECQL4, are 
associated with rare autosomal recessive disorders that are characterized by 
predisposition to cancer and premature aging (23). Interestingly, three disorders 
have been linked to mutations in the RECQL4 gene: Rothmund-Thomson-, 
RAPADILINO-, and Baller-Gerold syndromes, thus making RECQL4 unique within 
the RecQ family of DNA helicases. Although these disorders represent distinct 
genetic entities, clinical observations have depicted highly variable expressivity 
and significant overlaps in the associated phenotypes. Consequently, it is 
extremely difficult to unravel the precise genotype-phenotype correlation in 
RECQL4 related syndromes. This is likely due to the complex and multiple cellular 
networks RECQL4 is associated with. 
 RecQ helicases have been shown to unwind nuclear DNA structures 
resembling replication, transcription, and recombination intermediates (47). There 
is already much known about biochemical properties, interacting partners, and 
cellular localization of BLM and WRN helicase, although their exact cellular role is 
still under investigation. Progress in RECQL4 research is going much slower. After 
initial work about the cloning of the RECQL4 gene (36) and its association with 
RTS (33), only a few papers about RECQL4 function have been published: It was 
shown that purified RECQL4 protein from E.coli lacks helicase activity, but possess 
ssDNA strand annealing and ssDNA-dependent ATPase activity (190). By amino 
acid homology RECQL4 contains a conserved helicase domain. Unlike other RecQ 
homologues, RECQL4 lacks the conserved RQC (RecQ C-terminal) and HRDC 
(helicase and RNAse D C-terminal) domains necessary for nucleic acid binding 
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and unwinding (271-274). However, it still remains possible that RECQL4 needs 
co-activator proteins or a particular post-translational modification in order to 
accomplish a DNA unwinding function. It would be interesting to test whether 
RECQL4 purified from mammalian or insect cells possesses helicase activity. Two 
reports suggest that RECQL4 is essential for DNA replication and cell proliferation. 
The Xenopus RECQL4 orthologue, xRTS, accumulates at origins of DNA 
replication and is required for binding of DNA polymerase α to chromatin (177, 
178). Yin et al. demonstrated that RECQL4 interacts with cytoplasmic 
ubiquitinating proteins UBR1 and UBR2 (275) although the functional significance 
of this interaction is unclear. Our group recently reported that, in response to the 
induction of DSBs by etoposide treatment, a portion of RECQL4 and Rad51 
nuclear foci colocalized, suggesting that RECQL4 plays a role in the repair of 
DSBs by homologous recombination (181). 
 Taken together, only little information is available about the cellular role of 
RECQL4 protein and further studies are needed to draw a more precise picture 
about the function of RECQL4 protein to maintain genome stability. 
  
 We investigated if RECQL4 is subject to reversible acetylation and how this 
post-translational modification influences RECQL4 function in vivo. We found that 
RECQL4 and the histone acetyltransferase p300 physically and functionally 
interact. We purified RECQL4 from E.coli and our experiments confirmed a 
previous report showing that RECQL4 is a Mg+2– and ssDNA dependent ATPase 
(190). Surprisingly, preincubation of RECQL4 with purified p300 resulted in 
significant stimulation of the RECQL4 ATPase activity. However, the physiological 
consequence of this finding remains elusive. Further experiments could include the 
mapping of p300 domain that is crucial for the stimulation of RECQL4 ATPase 
activity. Additionally, it would be of particular interest to further investigate the 
consequence of p300 binding on the RECQL4 helicase activity. 
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 RECQL4 subcellular localization was studied extensively in the last couple 
of years (163, 181, 186, 275, 276). RECQL4 is the only human RecQ family 
member that is not entirely nuclear but also located in the cytoplasm of different 
cell lines examined (276). So far, the molecular mechanism by which RECQL4 is 
translocated to the cytoplasm and the cytoplasmic function of RECQL4 remains to 
be elucidated.  
 We could show that the RECQL4 NLS is spanning amino acids 376-386 
(KQAWKQKWRKK) and locates N-terminally of the helicase domain and p300 
mediated acetylation of several lysine residues inside the RECQL4 NLS positively 
regulates the translocation of RECQL4 from the nucleus to the cytoplasm. Our 
findings are consistent with previously published data indicating that lysine 
acetylation modulates the subcellular localization of several proteins (199). Lysines 
are important components of NLSs (277), because the positive charge mediates 
the interaction with importins (278). We hypothesize, as shown for transcription 
factors HMGB1 (265) and E1A (267), that p300-mediated acetylation negatively 
affects the function of the RECQL4 NLS (aa 376-386) and thus disrupts its 
association with the nuclear import machinery, which leads to subsequent 
cytoplasmic accumulation of RECQL4 protein. However, synchronizing cells at 
different stages of the cell cycle or treatment with different DNA damaging agents 
had no influence on the acetylation level of RECQL4 and the trigger for the 
RECQL4 acetylation by p300 remains unknown. Further studies might address the 
question of how RECQL4 acetylation is stimulated in vivo. Additionally, 
investigating RECQL4 localization in cells where p300 is transiently knocked-down 
by siRNA might help to further understand the role of RECQL4 acetylation in vivo. 
 Shuttling of proteins between the nucleus and the cytoplasm of cells 
involves highly regulated protein-protein interactions between the import/export 
machinery and the cargo-protein. It would be of particular interest to identify the 
RECQL4 nuclear export signal (NES) in order to elucidate the mechanism by which 
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RECQL4 is exported to the cytoplasm in mammalian cells and to fully understand 
the dynamic process of RECQL4 shuttling.  
 BLM and WRN are both subject to different posttranslational modifications 
like phosphorylation, SUMOylation and acetylation (85-90, 146, 152-158). For 
example BLM is phosphorylated after treatment of cells with ionizing radiation or 
HU in an ATM/ATR dependent manner. These checkpoint kinases phosphorylate 
target protein with the consensus motif S/TQ (154). The RECQL4 aa sequence 
contains several putative ATM/ATR phosphorylation sites and it is therefore very 
likely that RECQL4 is phosphorylated by those kinases. Future experiments could 
address this question as following: RECQL4 protein could be immunoprecipitated 
from whole cell extracts and assayed for phosphorylation using and anti-
phosphorylated-serine or threonine antibody. Furthermore, purified RECQL4 
protein could be phosphorylated in vitro using purified ATM/ATR kinase and γ-
ATP. Phosphorylated RECQL4 could subsequently be detected by 
autoradiography.   
 SUMO modifications, as shown for acetylation, take place at lysine residues. 
It would therefore be interesting to test if RECQL4 is SUMOylated in vivo and if 
SUMOylation would target the same binding sites as acetylation. 
 What might be the function of RECQL4 in the cytoplasm of human cells? 
RECQL4 is found in complex with UBR1/UBR2, two ubiquitin ligases that are part 
of the ubiquitin proteasome system, in cytosolic extracts of HeLa cells (275). It is 
therefore possible, that acetylation of RECQL4 could be a signal for its degradation 
in the cytoplasm. To address this question, we could test if acetylated RECQL4 
preferentially binds to UBR1/UBR2 and if acetylation has an influence on RECQL4 
poly-ubiquitination in vitro and in vivo.  Co-immunoprecipitation experiments and 
subsequent mass spectrometry analysis using cytosolic extracts from human cells 
could help to identify novel RECQL4 interacting partners and clarify the function of 
cytosolic RECQL4 protein. 
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